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Abstract
The enzyme xanthine oxidoreductase (XOR) has been implicated as a site of free 
radical generation in certain pathophysiological states, including chronic 
inflammation and ischaemia-reperfusion. However, investigations of its activity 
and location, particularly in human tissue, have been conflicting. There is, 
accordingly, a need for a means of detecting not only XOR enzymic activity, but 
also XOR protein, in tissue.
This thesis describes the generation of polyclonal and monoclonal (IgM) 
anti-(XOR) antibodies. An ELISA for XOR, with sensitivity in the nanogram 










ELISA Enzyme-linked immunosorbent assay
Fab Monovalent antigen-binding fragment of immunoglobulin molecule
following papain digestion 
FAD Flavin adenine dinucleotide (oxidized)
FADH2 Flavin adenine dinucleotide (reduced)
Fc Crystallizable, non-antigen binding fragment of immunoglobulin
molecule following papain digestion 
Fe/S Iron-sulphur redox centre
HRP Horseradish peroxidase
HX O  Human xanthine oxidoreductase
IFN-y Interferon-y
Ig Immunoglobulin
IgG Immunoglobulin class gamma






Mo-P Molybdo-pteridine redox centre
Mw Molecular weight
N A D + Nicotinamide adenine dinucleotide (oxidized)
NAD H Nicotinamide adenine dinucleotide (reduced)
ng Nanogram
NRS Normal rabbit serum
O 2- Superoxide anion radical
pAb Polyclonal antibodies
PBS Phosphate-buffered saline
PBS-T Phosphate-buffered saline with 0.1% (v/v) Tween-20
PMSF Phenylmethylsulphonyl fluoride
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Xanthine oxidoreductase (XOR) is a dimeric metalloflavoprotein. It is a 
molybdenum iron-sulphur flavin hydroxylase. Members of this enzyme group 




where RH  is the reducing substrate. The oxygen introduced into RH is from 
water and the electrons are accepted by the oxidizing substrate (Bray, 1975).
Xanthine oxidoreductase is the rate-limiting enzyme in nucleic acid 
degradation, catalysing the oxidation of hypoxanthine to xanthine, and xanthine 
to uric acid in the final stages of mammalian purine catabolism.
Most studies of XOR have used bovine enzyme (BXO) purified from 
milk (early studies reviewed in Bray, 1975; Massey et al., 1969; Hart et al., 1970; 
Nakamura and Yamazaki, 1982; Nishino et al., 1982; Ventom et al., 1988; H unt 
and Massey, 1992), rat liver (Della Corte and Stirpe, 1968, 1972; Stirpe and Della 
Corte, 1969; Waud and Rajagopolan, 1976a, 1976b; Ikegami and Nishino, 1986; 
Saito et al., 1989; Saito and Nishino, 1989; Amaya et al., 1990; Ichikawa et al., 
1992) and chicken liver (Nishino and Nishino, 1989; Schopfer et al., 1988) because 
of the ready availability of source tissue.
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More recently, studies have been initiated with human enzyme (HXO) purified 
from milk (Zikakis and McGinnis, 1988; Abadeh et al., 1992) and liver 
(Krenitsky et al.> 1986; Xu et al., 1994).
The enzyme monomer, molecular weight 150 kDa, has four redox 
centres:
• molybdo-pteridine
• two iron-sulphur clusters 2(Fe/S)
• flavin adenine dinucleotide (FAD).
These mediate electron transfer through the enzyme (Figure 1). Most reducing 
substrates interact at the molybdo-pteridine site and are hydroxylated as shown 
in the previous equation (Bray, 1975). N A D H  is not hydroxylated, but donates 
its electrons to the FAD in an oxidation reaction. Under physiological 
conditions, electrons are passed to oxygen or N A D + from the FAD centre. Some 
artificial electron acceptors, such as ferricyanide and methylene blue, can accept 
electrons from the Fe/S centres.
The predominant physiological form of XOR is xanthine dehydrogenase 
(XDH), which catalyses the oxidation of hypoxanthine or xanthine, with 
concomitant reduction of N A D + to NADH:
Hypoxanthine + H 20  + N A D + —> Xanthine + N A DH  + H +
The oxidase form (XO) uses molecular oxygen as an electron acceptor, producing 
superoxide anion radical and/or hydrogen peroxide:
Hypoxanthine + 2 0 2 + H 20  —> Xanthine + 0 2* + H 20 2 
Xanthine + 2 0 2 + H 20  —>Uric acid + 0 2'* + H 20 2
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Conversion of dehydrogenase to  oxidase occurs reversibly by oxidation of 
reactive sulphydryl groups (14 in each 150 kDa subunit), and irreversibly by 










































Figure 2. Interconversion of the various forms of X O R . From  Parks and 
Granger, 1986 (modified from  Della C orte and Stirpe, 1972).
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The XOR enzyme can exist in forms in which one of the redox centres is 
dysfunctional -  demolybdo, desulpho and deflavo (Bray, 1975).
Demolybdo-XOR lacks the molybdenum atom, but may retain some of the 
pteridine cofactor with which the molybdenum is normally associated (Ventom e t 
al.y 1988). However, adding molybdate to demolybo-preparations only restores 
molybdenum cofactor activity to approximately 33% of ‘normal5 enzyme activity, 
indicating that the molybdenum site is not free in most of the demolybdo- 
molecules (Ventom e ta l.y  1988).
Demolybdo-XOR occurs naturally (Hart e t al.y 1970; Bray, 1975; Abadeh et 
al.y 1992), and the ratio of demolybdo- to molybdo-containing-XOR in bovine 
milk appears to correlate with the nutritional status of the cow (Hart e t al.y 1970; 
Ventom e ta l.y  1988). Demolybdo-XOR does not oxidize xanthine, but can react 
with NADH, which donates its electrons directly to FAD.
Desulpho-XOR contains a Mo = 0  group in place of the Mo = S group of 
the ‘normal5 enzyme (Bray, 1975). As the same redox centre is compromised as 
that in demolybdo-XOR, this form has characteristics similar to those of the 
demolybdo-enzyme. Although this form was originally to be an artifact of 
preparation or storage, there is growing evidence for its in vivo presence in bovine 
and human milk (Massey and Edmondson, 1970; Wahl and Rajapolan, 1982; 
Abadeh e t al.y 1992), and speculation about its presence in other tissues (Abadeh 
e ta l.y  1992, 1993).
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Deflavo-XOR, unlike desulpho- and demolybdo-XOR, is an artificial 
form. As it lacks the FAD cofactor, it cannot catalyse the oxidation of NADH. 
Deflavo-XOR can be prepared by:
• selective removal of the FAD cofactor under conditions of high ionic strength 
(Komai et al., 1969)
• selective proteolysis with subtilisin at high pH  (also removing part of the 
protein; Nagler and Vartanyan, 1976)
• alkylation of the FAD by treatment with iodoacetamide or phenylacetate 
(McGartoll et al., 1970; Bray 1975).
Incubation of deflavo-XOR with flavin restores the native enzyme to 
approximately 85% of its original activity (Saito et al., 1989; Komai et al., 1969). 
This property has been exploited, by substituting ionizable or photoreactive 
FAD analogues, in order to study the FAD environment (Introduction 1.2.1; 
Nishino et al., 1989; Saito et al., 1989; 1992).
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1.2 Distribution and characteristics of XOR
Xanthine oxidizing activity, similar to that found in eukaryotic XOR, has been 
detected in a variety of bacterial species -  both Gram-negative and Gram-positive 
(Woolfolk and Downard, 1977). Activity has also been detected in invertebrates, 
but here the relative efficacy of the electron acceptor (i.e. N A D +, ferricyanide or 
Oj) varies widely between species (Krenitsky et al., 1974).
Birds, reptiles, amphibians and teleosts contain XOR with the following 
relative electron acceptor specificities: N A D + > ferricyanide >  0 2 (Krenitsky et 
al., 1974). In the same study, Krenitsky et al. (1974) reported the mammalian 
enzyme to have the electron acceptor specificity pattern:
ferricyanide >  0 2 > N A D +, though they did not comment on the evolutionary 
significance of the patterns.
The emphasis of much of the work on XOR has concerned its 
distribution in mammalian tissues. As the focus of this project is on mammalian 
XOR, it is useful to summarize the results of previous studies on model 
mammalian species.
1.2.1 Rat
The presence of XOR in rat tissues has been described by many groups (early 
studies reviewed in Kooij A, 1994; Battelli et al., 1972; Brunschede and Krooth, 
1973; Krenitsky et al., 1974; Kinuta et al., 1989; Smith et al, 1989; Kooij et al, 
1992a).
A comprehensive survey of rat tissues, using a specific histochemical 
method for XOR activity, indicated absence of enzyme in only the bladder,
cerebrum, cerebellum and aorta (Kooij et al., 1992a). All other tissues showed 
positive staining, with high activity in epithelial and endothelial cells, and 
connective tissue.
Total XOR activity (i.e. XDH and XO) in liver is reported as 340 m U /g 
tissue, when 1 unit of enzyme activity corresponds to the formation of 1 pimole 
of product/minute (Battelli et al., 1972). Total XOR activity of skeletal muscle 
(from hindquarters) is 11.0 m U /g wet weight of tissue (definition of activity as 
before; Smith et al., 1989), while that of rat brain is 0.87 m U /g wet weight of 
tissue (Kinuta et al., 1989).
Intracellularly, the enzyme has been located, using immunoelectron 
microscopy, in the cytoplasm of endothelial cells lining capillaries and small 
blood vessels in rat myocardium (Samra et al., 1991). Cytosolic location of XOR 
has similarly been detected in rat hepatocytes (Ichikawa et al., 1992).
Heart has been a focus of much attention because of the purported role of 
XOR in human ischaemia-reperfusion (I-R) injury (Introduction 1.3.1). Activities 
of the cardiac enzyme reported by different groups are summarized in Table 1.
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A uthor
Total XOR activity 




Schoutsen et al., 1983 18 radiochemical HPLC (isolated, perfused) 30°C
Schoutsen et al., 1983 10 radiochemical HPLC (homogenate) 30°C
Schoutsen etal., 1983 27 radiochemical HPLC (homogenate, low 
Mw inhibitors removed)
30°C
Grum etal., 1986 62 radiochemical (homogenate) 37°C
Kaminski etal., 1986 28 spectrophotometric (homogenate) 25°C
Muxfeldt and Schaper, 1987 20 HPLC (homogenate) Room temperature
Eddy etal., 1987 47 spectrophotometric (homogenate) N ot reported
Eddy et al., 1987 77 fluorimetric (homogenate) N ot reported
de Jong etal., 1990 29 HPLC (isolated, perfused) 37°C
Table 1. Reported values of XOR activity in rat heart. One unit (U) of enzyme activity corresponds to the formation of 1 pmol of 
product/minute.
Kaminski et al., (1986) reported that, with phenylmethylsulphonyl fluoride 
(PMSF) and dithiothreitol (DTT) included in the rat heart homogenization buffer, 
the dehydrogenase form accounted for 85.2% total XOR activity in rat heart, with 
oxidase accounting for 7.5% of activity. These workers also reported the presence 
of the intermediate form (7.2%), which preferentially transferred electrons to 
N A D + but, in the absence of this electron acceptor, could transfer electrons to 
oxygen. They found all three enzyme forms to be interconvertible on incubation 
with sulphydryl-modifying agents (in the absence of protease inhibitors). This 
indicates that the oxidase form in rat heart is the reversible, rather than the 
irreversible type.
The primary structure of rat liver XOR has been described (Amaya et al., 
1990). Freshly purified enzyme is dehydrogenase and comprises 1319 amino acid 
residues (Mw= 145 kDa). Trypsin digestion results in nicks in the sequence at 
residues 184-5 and 539-40 (Amaya etal., 1990; Nishino and Tamura, 1991). 
Subsequent sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
P AGE) of the fragments indicates the molecular weights of the three fragments 
produced, are 20 kDa, 40 kDa, and 85 kDa, corresponding to residues 1-184, 185— 
539 and 540-1319, respectively. That the three peptide fragments do not dissociate 
on trypsin digestion demonstrates a strong association between them.
The FAD cofactor and N A D + binding site are associated with the 40 kDa 
fragment; the 2 Fe/S sites are associated with the 20 kDa fragment and the 
molybdo-pteridine is associated with the 85 kDa fragment (Amaya et al., 1990; 
Nishino and Tamura, 1991).
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It has been suggested that the cysteine residues in the 20-kDa fragment contribute 
to the 2 Fe/S redox centres (Amaya et al., 1990). These residues, and the 
surrounding amino acid sequences, are well conserved between the rat and 
Drosophila melanogaster enzymes (Amaya et al.> 1990). In total, the 20-kDa 
fragment of the rat enzyme has 66% homology with that of D. melanogaster 
(Amaya et al., 1990). The 40-kDa fragment has less homology, with the amino acid 
sequence corresponding to the N A D + binding site differing between the XDH of 
D. melanogaster and rat. Identity between the 85 kDa fragments is 52% (Amaya et 
a l , 1990).
Nishino and Tamura (1991) report that, on treatment with 
fluorodinitrobenzene, a nucleophilic reagent, reversible conversion from XDH to 
XO occurs (Figure 3). This conversion corresponds to modification of the cysteine 
residues Cys525,980,1313 and led the authors to speculate on the existence of a 
disulphide bridge between Cys5i> and Cys980.
22
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F igu re  3. C onform ational change by proteolysis, sulphydryl oxidation or N A D  + 
binding. F rom  N ishino and Tam ura (1991).
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Further evidence for the role of disulphide bridges in the dehydrogenase 
to oxidase conversion comes from studies using reconstituted XOR from deflavo- 
XOR and FAD. Holoenzyme reconstituted from non-DTT-reduced deflavo-XOR 
is wholly oxidase in nature, and has no activity towards N A D + (Saito et al.,
1989). O n incubation with DTT, N A D +-dependent activity reappears, with 
conversion of XO to XDH estimated as 60-70% (Saito et al., 1989). Similarly, 
holoenzyme reconstituted from DTT-treated deflavo-XOR is largely 
dehydrogenase.
In the dehydrogenase enzyme, FAD is stabilized in the semiquinone state 
by flavin-protein interactions (Waud and Rajagopolan, 1976a; Nishino et al.,
1989; Saito and Nishino, 1989). Under standard assay conditions, the Km for 
oxygen of the dehydrogenase enzyme is 260 /xM, whereas that for the oxidase 
form is 46 /xM (Saito and Nishino, 1989). This difference in affinity for oxygen 
is, most probably, due to the conformational changes around the FAD site. 
Conformational change could directly affect the reactivity of the FAD with 
molecular oxygen and/or alter the accessibility of the active site (Saito and 
Nishino, 1989).
On conformational modification, by proteolysis or sulphydryl oxidation, 
the stable form of FAD is fully reduced; FADH2 reacts rapidly with oxygen to 
form hydrogen peroxide, rather than the superoxide anion radical formed by the 
semiquinone state (Nishino et al., 1989; Saito and Nishino, 1989; Nishino and 
Tamura, 1991). The presence of N A D + also causes conformational change in the 
enzyme, again making fully reduced FAD the more stable state. This then 
rapidly reduces N A D + (Nishino and Nishino, 1989; Saito et al., 1989).
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1.2 .2  C o w
Xanthine oxidoreductase has been located, using immunochemical procedures, in 
the capillary endothelial cells of bovine mammary gland, liver, heart, lung, 
intestine and in epithelial cells of lactating mammary gland (Jarasch et al., 1981; 
Bruder etal., 1982; Bruder etal., 1983).
Bovine milk, particularly, contains high levels of BXO -  around 
50 mg/litre (Bray, 1975) -  and enzyme activity is much higher than that of other 
bovine tissues (Table 2).
Fraction
BXO activity 
(m U /m g protein) Supernatant protein (%)
liver 1.4 0.1
milk (lipid globule 
preparation)
1.1 x 103 61
lactating mammary gland 2.8 1





Table 2. BXO in a range of tissues (from Bruder et al., 1983). Activity was 
determined spectrophotometrically at 30°C; 1 unit (U) corresponds to the 
formation of 1 pmol urate/minute.
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In milk, BXO has been localized to the lipid globule and lipid globule 
membrane, with the forms termed, respectively, ‘soluble* and ‘membrane bound’ 
(Briley and Eisenthal, 1974; Bruder et al., 1982). Briley and Eisenthal (1974) 
reported that the catalytic activities of the milk enzyme depended on its location, 
with the membrane-bound enzyme having enhanced N A D H  oxidation relative to 
that of xanthine. They used the ratio of xanthine oxidation to N A D H  oxidation 
(X/N) to distinguish between the two forms, and demonstrated that the X /N  
ratio decreased when free enzyme was incubated with a membrane preparation. 
Similar experiments indicated that only one type of binding site exists within the 
membrane, sites are independent, and that binding is reversible.
The enzyme found in endothelial cells appears similar to the milk form 
(Bruder et al., 1982). As in milk, soluble and membrane-bound forms exist 
(Jarasch et al., 1986). Although the enzyme purified from milk is usually 100% 
oxidase in nature, conversion to dehydrogenase can be achieved by incubation 
with DTT. The enzymic properties of BXO from milk are similar to those 
described for rat liver enzyme (Introduction 1.2.1).
Surprisingly, in view of the intensive study of BXO and the ready 
availability of bovine milk, enzyme from this source has only very recently been 
sequenced (Berglund et al., 1996). Crystallization and X-ray diffraction studies are 
now underway (Eger et al., 1994) and it is hoped that information on the three- 
dimensional structure will soon be available.
26
1.2.3 Rabbit
Xanthine oxidoreductase activity has been reported in rabbit liver, small intestine 
and kidney (Krenitsky et al., 1974). As with other model species, attention has 
focused on rabbit heart because of the potential role of the enzyme in human 
ischemia-reperfusion injury (Table 3).
Author




de Jong etal., 1990 0.59 HPLC, 37°C 
(isolated, perfused)
Downey etal., 1987 none spectrophotometric, 37°C 
(homogenate)




0.05 HPLC, room temperature 
(homogenate)
Schoutsen and de 
Jong, 1987
3 x ia 3 radiochemical HPLC, 30°C 
(homogenate)
Terada, 1994 ~ 98 HPLC, 37°C (butanol 
extracted homogenate)
Terada, 1994 ~ 54 HPLC, 37°C 
(homogenate)
Wajner and Harkness, 
1989




Table 3. Reported values of XOR activity in rabbit heart; 1 unit (U) corresponds 
to the formation of 1 pmol urate/minute, except where indicated.
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Rabbit heart, in comparison with reported values of XOR activity in rat 
heart (Table 1), has very low XOR activity, though reported values vary (Table 3). 
Reporting the highest activity, Wajner and Harkness (1989) used an assay mixture 
containing a high concentration of substrate. This led the authors to speculate on 
the presence, in the test sample, of a high-molecular-weight cytosolic enzyme 
inhibitor, the effects of which could be overcome at high substrate concentrations.
Terada (1994) reported XDH inhibition associated with an endogenous 
compound (M w =  3 7 0  kDa). By following the fate of N A D + in the presence of 
rabbit heart homogenate, Terada demonstrated that the suppression of 
dehydrogenase activity was associated with NADase activity, and speculated that it 
may be due to the action of a glycohydrolase. Incubation of the homogenate 
fraction with BXO (from milk) also suppressed dehydrogenase activity. The 
NADase activity was heat and acid labile, and was removed by butanol extraction.
1.2.4 Human
Xanthine oxidoreductase activity has been detected, using biochemical methods, in 
human liver, intestine, spleen, kidney and skeletal muscle (Watts et al., 1965; Della 
Corte et al., 1969; Krenitsky etal., 1974; Mousson etal., 1983). More recently, 
Kooij et al., (1992b) have used a histochemical assay to demonstrate H XO activity 
in the liver and jejunum, but failed to detect activity in a range of other tissues.
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Immunohistochemical techniques have localized the enzyme in the 
cytoplasm of endothelial cells lining the capillaries of heart kidney, brain, aorta, 
lung, mesentery, sinusoids, and alveolar epithelial cells of mammary gland 
Qarasch et al., 1986; Moriwaki et al., 1993), and in vascular smooth muscle cells, 
macrophages and mast cells (Hellsten-Westing, 1993).
In addition, HXO located on the outer surface of the endothelial cell 
plasma membrane, has been reported (Adachi et al., 1993). Its association with 
the plasma membrane is, reportedly, via heparin-like proteoglycans.
In human liver, XOR has specific activity comparable with that reported 
for bovine milk (1.8 U /m g HXO protein compared with 2.4-5.1 U /m g BXO 
protein; BXO data reviewed in Bray, 1975; Krenitsky et al., 1986). Human XOR 
has been reported in milk at the level of 1.5-6 mg/100 ml (Abadeh et al., 1992), 
and 6-14 mg/100 ml (Brown et al., 1995). Ninety-eight per cent of this H X O  is 
inactive towards xanthine (Abadeh et al., 1992); this is high in comparison with 
that reported (up to 60%) for BXO (Hart et al., 1970; Bray, 1975). When N A D H  
is used as the reducing substrate in assays of enzyme activity, however, the 
specific activities of both HXO and BXO from milk sources, are comparable 
(Table 4; Abadeh et al., 1992). When activity is detected by measurement of urate 
or isoxanthopterin production, the assumption is that the enzyme has a 
functional molybdo-pteridine redox centre and, therefore, demolybdo and/or 
desulpho enzyme forms will not be detected by these assays. If the enzyme exists 
mostly in these forms in a given tissue, results from conventional assays of 
activity will be unreliable.
29
Assay substrate Assay electron acceptor H X O  activity 
(m U /m g protein)
BXO activity 
(m U /m g protein)
xanthine N A D + 24 1060
xanthine oxygen 15 524
xanthine methylene blue 15 2440
xanthine cytochrome c 106 1850
N A DH oxygen 39 31
NAD H methylene blue 149 244
N A DH cytochrome c 118 138
Table 4. Comparison of specific activities of HXO and BXO purified from milk (Abadeh et al., 1992); 1 unit (U) corresponds to 
the formation of 1 pmol urate/minute. Assays were performed at 22°C.
As with rabbit, reported values of HXO activity in human heart vary 
(Table 5). The presence and activity of HXO in human heart has become an 
issue of debate. It has been suggested that desulpho- and demolybdo-XOR, in 
similar proportions to those in human milk, may exist in the heart (Abadeh et 
al., 1992); preliminary work in our laboratory supports this theory (Abadeh et al, 
1993). Thus, in humans at least, varying amounts of different forms of XOR may 
exist, in vivo , in different tissues.
Interconversion between sulpho- and desulpho-XOR has been suggested as 
a means of molecular regulation of XOR activity (Itoh et al., 1978; Furth-Walker 
and Amy, 1987; Brown et al., 1995). By transferring sulphide ions, sulphur 
transferases could, for example, mediate regulation. Further studies are necessary 
to establish whether such interconversions can occur in vivo in human tissue.
Evidence for the interconversion between different forms of H XO was 
recently provided (Brown et al., 1995). Activity and amount of H X O  was 
measured in serial milk samples from women who had just given birth. Activity 
of the enzyme increased to a peak value and then decreased to basal level 
approximately 15 days post-parturition. Interestingly, corresponding reduction in 
HX O  protein was not observed, suggesting activation-deactivation was occurring 
at the molecular level, possibly as a result of hormonal control.
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Author Total XOR activity 
(mU/g wet weight)
Assay and assay temperature 
(heart preparation)
Eddy et al., 1987 0 spectrophotometric, fluorimetric, temperature 
not reported (homogenate)
Muxfeldt and Schaper, 1987 1.3 HPLC, room temperature (homogenate)
Grum etal., 1989 0 radiochemical, 37°C (homogenate)
Wajner and Harkness, 1989 1.2 mU/mg protein (—37) spectrophotometric, 25 °C (homogenate)
de Jong etal., 1990 0.3 HPLC, 37 °C (isolated, perfused)
Podzuweit etal., 1991 0 HPLC, 25°C (homogenate)
Kooij et al., 1992b negative histochemical
Hellsten-Westing, 1993 positive (vascular smooth muscle cells, capillary 
endothelial cells, small venules and arterioles)
immunohistochemical
Moriwaki et al., 1993 positive (endothelial cells) immunohistochemical
Table 6. Reported activity and location of XOR in human heart; 1 unit (U) corresponds to the formation of 1 pmol 
urate/minute, except where indicated.
Recently, cDNA clones of human liver xanthine dehydrogenase have been 
isolated and sequenced, (Ichida etal., 1993; Xu etal., 1994). The 1333 amino acid 
sequence (Mw= 147 kDa) has 91% homology with rat XDH (Xu et al., 1994). The 
trypsin cleavage sites are conserved, occurring between residues Lys1>l5 and AspIS6, 
and at Lys552 in the human sequence (Ichida et al., 1993; Xu et al., 1994). The 
cysteine residues Cys43, 4 8 ,5 1 ,7 3 and Cys1 5 0 ,1 6 9 ,175 in the N-terminal region 
contributing to Fe/S centres I and II respectively, are also well conserved between 
rat and human (Xu et al., 1994). The consensus N A D + -binding site is located at 
residues 389-401 in the human sequence (Xu etal., 1994). The sequence Gly-Xaa- 
Gly-Xaa-Xaa-Gly, contributing a PaP helix formation in NAD-binding region of 
mouse and rat X DH has been described (Amaya et al., 1990; Terao et al., 1992), and 
is conserved in the human sequence at residues 42-47 and 796-801 (Xu et al., 1994). 
The molybdenum binding site is also well conserved between rat and human, 
occurring in the 85-kDa fragment (Amaya etal., 1990; Xu etal., 1994).
Using N orthern blot analysis, the tissue expression of the XDH gene has 
been studied (Ichida et al., 1993; Xu et al., 1994). The gene, which is located on 
chromosome 2  (Ichida et al., 1993), is expressed in all tissues including the heart, 
brain, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, 
ovary, small intestine, colon, and also in the placenta (Xu et al., 1994).
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1.3 Role of XOR as a source of reactive oxygen species
Free radicals are molecules, or molecular fragments, containing unpaired electrons 
in the outer orbit; they can act as an oxidants or reductants. These chemically 
reactive species can initiate chain reactions which can result in irreversible 
structural damage to lipid and protein.
Reported sources of free radicals, in addition to the XOR system, include 
activated neutrophils (McCord 1987), the reduced mitochondrial electron 
transport chain (donating electrons directly to molecular oxygen), catecholamine 
oxidation, prostaglandins and drugs such as doxorubicin (Kukreja and Hess 1992). 
Where the balance between free radical generation and neutralization is 
disrupted, tissue damage may occur. Free radical-mediated tissue damage has been 
implicated in I-R  injury (McCord, 1985) and has been cited as contributing to 
the pathobiology of a number of diseases including myocardial infarction, 
rheumatoid arthritis, pancreatitis and atherosclerosis (reviewed in Kooij, 1994).
1.3.1 A hypothesis of XO-mediated damage during I-R  
(McCord, 1985)
During ischaemia, the ATP level in a cell diminishes and the AMP concentration 
increases concomitantly. The AMP is then catabolized to adenosine, inosine and, 
finally, hypoxanthine -  a substrate of XOR. The drop in ATP concentration also 
results in disturbance of the ionic gradients across the cell membranes which, in 
turn, causes a redistribution of calcium ions within the cell. High cytosolic 







dehydrogenase enzym e form  to  the oxidase form.
O n  restoration of blood flow, molecular oxygen becomes available to  the 
oxidase form  enabling it to  oxidize hypoxanthine, producing superoxide anion 
an d /o r  hydroxyl radicals (Figure 4).
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Figure 4. A hypothesis of XO-m ediated damage during I-R (McCord, 1985).
1.3.2 Inhibition studies
The major evidence for the involvement of XO-mediated free radical damage in I- 
R comes from studies using the XOR inhibitor, allopurinol 
(4-hydroxypyrazolo[3,4-flf]pyrimidine). Allopurinol is an altemative-substrate 
inhibitor, competing with hypoxanthine and xanthine for the substrate binding 
site; XOR oxidizes allopurinol to oxypurinol (4,6-dihydroxypyrazolo[3,4- 
^fjpyrimidine), which is a non-competitive inhibitor. Reports of allopurinol and 
oxypurinol acting as direct free radical scavengers do, however, require that reports 
of beneficial effects on infarct size should be rigorously assesed before firm 
conclusions from allopurinol inhibition studies can be drawn (Moorhouse etal., 
1987; Hoey etal., 1988; Grootveld etal., 1988).
Chronic administration of allopurinol (i.e. 18-24 hours prior to coronary 
artery occlusion) has been reported to limit infarct size in the canine model of I-R  
(Akizuki etal., 1985; Chambers etal., 1985; Wems etal., 1986). The nature of the 
inhibitory effect exerted by allopurinol has been questioned (Wems et al., 1991). 
When allopurinol was administered to dogs shortly (i.e. 30 minutes) before 
coronary artery occlusion, no effect on infarct size was observed (Reimer and 
Jennings, 1985). In contrast, short-term administration of oxypurinol has been 
reported to limit infarct size following I-R  (Wems et al., 1991). However, the same 
authors demonstrated that this was not due to XOR inhibition as amflutizole, an 
XOR-inhibitor chemically unrelated to allopurinol, failed to limit infarct size 
under the same conditions (Wems etal., 1991; Wems and Lucchesi, 1990). 
Amflutizole inhibition of XOR in rat heart has, however, been reported to protect
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against reperfusion-induced arrhythmias associated with free radical production 
(Manning etal., 1988).
In species where the existence of XOR in heart is controversial, conflicting 
theories have arisen as a result of inhibition studies. Some groups report that 
allopurinol does not limit infarct size in the rabbit (Yellon etal., 1985; Downey et 
al., 1987), while Terada et al., (1991) report that allopurinol does have protective 
effects. Using explanted human hearts perfused with hypoxanthine, de Jong et al., 
(1991), demonstrated low HXO activity, concluding that HXO-mediated cardiac 
damage was unlikely to occur. Johnson et al., (1991), however, described a 
beneficial effect of allopurinol administered to patients undergoing bypass surgery.
Human umbilical vein endothelial cells (HUVEC) have been proposed as a 
good in vitro model for endothelial cells in vivo (Michiels et al., 1992). Using these 
cells, parameters of cell viability and free radical production were reported under 
different conditions; allopurinol was reported to completely inhibit superoxide 
production (Michiels et al., 1992). The authors also report a measurable XO 
activity following, but not preceding, ischaemia.
1.3.3 NADH oxidase activity of XOR
The major assumption of the above model of XOR-mediated free radical damage 
following I-R  is that the conversion of XDH to XO occurs rapidly enough to 
account for the free radical production reported. The rate of XDH to XO 
conversion in ischaemic rat intestine is, reportedly, rapid with complete 
conversion occurring in less than 1 minute (Roy and McCord, 1983). The speed 
and efficiency of the conversion have, however, been questioned as Nishino and
Tamura (1991), could only demonstrate conversion in post-I-R dog lung of around 
30% at maximum.
The N A D H  oxidase activity of XOR also results in superoxide generation 
(Nishino and Tamura, 1991; Abadeh et al., 1992), and a case can be made for free 
radical generation via N A D H  oxidase activity during post-ischaemia reperfusion.
•  Physiological NA D H  levels increase during ischaemia and the N A D +/N A D H  
ratio decreases from 700 to 30 (Nishino and Tamura 1991).
•  Xanthine dehydrogenase is more efficient than XO in oxidizing NADH 
(Powell, 1996), and XDH to XO conversion is not required.
•  H XO is reported as having low activity when assayed using conventional 
measurement of urate production, but has NADH activity comparable with 
that of BXO (Table 4; Abadeh etal., 1992).
• NADH oxidase activity is not inhibited by conventional XOR inhibitors 
(Powell, 1996), and evidence based on allopurinol, oxypurinol or amflutizole 
inhibition is irrelevant to a pathogenic mechanism based on NAD H  oxidation.
•  Naturally occurring desulpho enzyme can oxidize NADH but not 
hypoxanthine or xanthine. In vivo mechanisms of conversion between 
holoenzyme and desulpho XOR have yet to be determined.
Thus, while the 20-30% of XOR existing as, or converted to, XO in vivo may 
follow the McCord model, NAD H  oxidation, which does not require X DH—»XO 
conversion may also contribute. The balance between these two activities may 
explain some of the incongruous results of various inhibition studies.
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1.3.4 Inflammation -  a reported role for XOR
During the acute inflammatory process, activated neutrophils permeate the 
vascular wall and adhere to endothelial cells at and around the site of 
inflammation. The stimuli that attract the neutrophils to the site of inflammation 
also induce changes membrane that promote fusion of the neutrophil granule 
membrane, and subsequent exocytosis of the granules’ contents.
Incubation of stimulated neutrophils with extracts of rat pulmonary artery 
endothelial cells has been shown to increase XO activity without increasing the 
total XOR activity (Phan et al., 1989). Further experiments have implicated 
neutrophil elastase as the mediator of this conversion, as incubation of whole 
endothelial cells w ith purified neutrophil elastase caused a similar increase in XO 
activity (Phan et al., 1992). Elastase is present in neutrophil granules and, on 
exocytosis, pericellular levels of elastase increase. As a result of the 
neutrophil/endothelial cell association, it has been suggested that neutrophil 
elastase enters the endothelial cell and causes the conversion of XDH to XO (Phan 
etal., 1992).
In opposition to the McCord theory of XO-mediated cellular damage 
during I-R, Phan et al. (1994), demonstrated that the action of intracellular calcium 
proteases was not sufficient to cause the observed XDH to XO conversion. 
Activated neutrophils generate reactive oxygen species via NADPH oxidase located 
on the extracellular side of the plasma membrane. The superoxide anion radical 
produced by NA D PH  oxidase dismutates to hydrogen peroxide, which may then 
diffuse into the endothelial cell (Varani etal., 1990).
+ le'
O f. + 2H + -> H 2O 2
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An effect of hydrogen peroxide within the cell is to diminish cellular ATP 
reserves, with a consequent increase in the concentration of XOR substrates, 
xanthine and hypoxanthine (Varani et al., 1990). Xanthine oxidase-generated 
superoxide anion radicals can react with ferric iron to produce ferrous iron which 
can then react with NA D PH  oxidase-generated hydrogen peroxide to produce 
ferric iron and the highly reactive hydroxyl radical.
The whole reaction sequence is termed the Haber-Weiss reaction.
O f. + 2H + —> H 2O 2 
Of* + Fe3+ — > 0 2  + Fe2+
H 2O 2 + O 2 + Fe2+-> Fe3+ + HO*
Intracellular free radicals can react with plasma membrane lipids to produce 
the chemotactic agents that attract neutrophils to the site of inflammation (Perez et 
al.y 1980). Thus, XO may amplify the inflammatory response by recruiting 
increasing numbers of neutrophils to the locale.
A similar hypothesis links free radical-stimulated neutrophil recruitment to 
I-R injury (Granger, 1988; Korthuis and Granger, 1993). Oxidants generated by 
XO on reperfusion, initiate and/or upregulate pro-inflammatory agents which 
attract and activate neutrophils. As described above, the combination of NADPH 
oxidase and XO activities can result in the generation of the highly destructive 
hydroxyl radical.
The oxidative effects of free radicals within a pathophysiological 
environment are likely to be highly damaging and wide-ranging, as illustrated by 
the scenario proposed for oxidative damage in inflammatory joint disease 














Serpin inactivation/glycosaminoglycan degradation 
Cytoskeleton/vimentin change 
Lipid peroxidation— >• anergy/proliferation/ fibrosis 
Osteoclast activation-► bone resorption
D N A  dam age----------- ► proliferation
N F k B  activation  ► cytokine release
Figure 5. Proposed mechanisms of free-radical-mediated damage in inflammatory 
joint disease (Winrow et a l 1993).
1.3.5 The effect o f cytokines and a glucocorticoid on X O R  activity
In addition to direct XDH to XO conversion, XOR activation by inflammatory 
mediators has also been reported (Dupont et al., 1992; Pfeffer et a l 1994). The 
effect of cytokines and steroids on XOR activity has been studied using cultured 
rat lung endothelial cells and bovine renal epithelial cells (Dupont et al., 1992; 
Pfeffer et a l 1994) as model systems.
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Dupont et al. (1992) reported that, though cultured rat lung microvascular 
cells have low levels of XOR activity (approximately 2.0 m U /g protein), 24-hour 
exposure to 1000 U /m l interferon-y (IFN-7 ) increased activity fivefold. Xanthine 
oxidase activity contributed approximately 20% of the activity before stimulation, 
and this ratio was maintained following IFN-y stimulation. Northern blot 
analysis showed increased levels of XOR mRNA on EFN-y stimulation, 
indicating upregulation of mRNA transcription. Actinomycin D and 
cycloheximide abolished the effect of IFN-y on XOR activity, providing further 
evidence that transcription of the XOR gene increases as a result of IFN-y 
stimulation. Dupont et al. (1992) also demonstrated that cycloheximide, alone and 
in combination with IFN-y, increased XOR mRNA levels. This result indicates 
that a constitutively produced repressor protein, or protein with RNase activity, 
may regulate XOR expression.
Similar results have been reported for bovine renal epithelial cells (Pfeffer 
et al., 1994). Again, 1000 U /m l IFN-y increased XOR activity from 
approximately 40 m U /g protein to 57 m U /g protein, with XO accounting for 
40-50% total activity both before and after stimulation. Similarly, cycloheximide 
was shown to increase the level of XOR mRNA. Unlike Dupont et al. (1992), 
however, Pfeffer et al. (1994) also found that exposure to TNF, IL-1 and IL-6 also 
increased X OR activity in cells by transcriptional upregulation. Furthermore, it 
appeared that these cytokines had an additive effect on XOR activity, though the 
mechanisms by which this occurred were not investigated.
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Dexamethasone, a glucocorticoid, also stimulates XOR transcript ■ 
expression and activity, acting apparently via a glucocorticoid receptor (Pfeffer et 
al., 1994). This result complicates the hypothesis that XOR-generated free radicals 
contribute to tissue damage during inflammation, as dexamethasone is an anti­
inflammatory agent.
The reported effects of cytokines and a glucocorticoid on XOR activity, 
together with the actions of proteases and the postulated actions of sulphydryl 
modifiers, suggest that XOR activity may be controlled at two levels:
• transcriptional level -  upregulation via cytokines and glucocorticoids, and the 
action of a repressor protein
• tertiary level -  conformational modification resulting in XDH to XO 
conversion.
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1.4 Aims of the project
Xanthine oxidoreductase is constitutively expressed in a wide range of cells. Its 
‘dual nature’ and properties have interested researchers for many decades, and its 
involvement in different diseases and pathological responses has been postulated.
Research into the conversion of the dehydrogenase form to the oxidase 
form, transcriptional activation and regulation via conversion from inactive to 
active forms, has made the study of XOR both complex and exciting. We still do 
not know which is the most important role of the enzyme. It could be production 
of the antioxidant, uric acid, or it could involve its ability to produce free radicals 
under certain conditions. Knowledge of XOR regulation will contribute to our 
understanding of why the enzyme exists.
In order to establish the level of regulation and activation of XOR, we must 
follow both activity and levels. The aim of the project was to generate monoclonal 
and polyclonal anti-(XOR) antibodies (mAbs), recognising different enzyme 
epitopes which could be used, in ELISA, to quantitate the enzyme in mammalian 
tissues and cell culture systems. ELISA was chosen as the assay of choice as this 
method is convenient, safe, reproducible and relatively inexpensive. Quantitative 
data would complement kinetic assays of enzyme activity in experiments designed 
to address the mechanisms of regulation of XOR. The anti-(XOR) antibodies were 
also required for affinity purification of XOR from tissue, and methods for each 
purification were to be investigated. Again, immunoaffinity chromatography is a 
powerful yet simple method for isolating proteins.
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2 Materials and methods
2.1 Preparation of standard solutions
All chemicals were purchased from Sigma Chemical Co. Ltd, unless otherwise 
stated. Addresses of suppliers are given in Appendix I.
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2.2.1 Protein estimation -  Lowry method (modified from Lowry et 
a l , 1951)
A series of standard protein solution dilutions from 0-200 jig/200 /d was 
prepared, from a 1  mg/ml stock, in the same buffer as the test sample. The 
reference protein was either bovine serum albumin or a standard concentration 
of BXO. A volume of cupric sulphate 1% (w/v) was added to an equal volume 
of sodium potassium tartrate 2 % (w/v). This was mixed 1:50 with sodium 
carbonate 2 % (w/v) in 0.1 M sodium hydroxide prior to the assay. O f this 
solution, 1 ml was added to the 200 /d protein standard or test sample. After 
incubation for 10 minutes at room temperature, 100 /d Folin and Ciocalteu’s 
Phenol reagent [50% (v/v); BDH Chemicals Ltd] was added. The tubes were 
vortex mixed and incubated for 30 minutes. Samples (100 /d) were transferred to 
a 96-well plate and the colour reaction was quantitated by a Dynatech Mini-skan 
II ELA plate reader (Labsystems) at 690 nm. The unknown protein concentration 
could be determined from a reference plot of absorbance at 690 nm against 
protein concentration for the standard solution.
Precipitation occurred with some buffers and in these cases, the 
supernatant was used where possible. A sample reference curve is shown 
(Figure 6 ) with average values from two assays using different stock solutions and 
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Figure 6. Protein content estimation using a method modified from Lowry et al., (1951).
The points represent the means of duplicate assays, and the vertical bars indicate the range of values.
2.2.2 Protein estimation -  Bradford method (modified from 
Bradford, 1976)
When interference occurred using the Lowry method of protein estimation, the 
Bradford dye-binding assay was substituted.
Bovine serum albumin or BXO was used as the standard protein solution. 
The standard was diluted over a range 0-100 /xg in a sample volume of 
1 0 0  /xl. The volume of test sample was adjusted to a final volume 1 0 0  /d. O f the 
Bio-Rad dye [20% (v/v); Bio-Rad Laboratories Ltd], 1 ml was added to each 
sample and the mixture was vortex mixed. After 15 minutes, 100 /xl samples were 
transferred to a 96-well plate and the A595 was measured using the Dynatech plate 
reader. The protein concentration in the test sample was estimated from a 
reference plot of A 595 against protein concentration of the standard dilutions.
When test sample volumes were small, the assay was scaled down by a 
factor of 10 and performed in a 96-well plate.
Again, a sample reference curve is shown (Figure 7) with average values 
from two assays using different stock solutions and performed on different days. 
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Figure 7. Protein content estimation using a method modified from Bradford (1976).
The points represent the means o f duplicate assays, and the vertical bars indicate the range o f values.
2.2.3 SDS-PAGE (modified from Laemmli, 1970)
Vertical gels, 10% separating gel and 5% stacking layer, were prepared routinely. 
The separating gel comprised 1 0 % (w/v) acrylamide (Protogel 37.5:1 acrylamide to 
methylene bisacrylamide solution; National Diagnostics), 0.375 M Tris-HCl, pH 
8 .8 , 1% (w/v) SDS, 0.06% (v/v) TEMED, 0.03375% (w/v) ammonium persulphate. 
The stacking layer comprised 5% (w/v) acrylamide (Protogel), 0.125 M Tris-HCl, 
pH 6 .8 , 0.1% (w/v) SDS, 0.1% (w/v) TEMED, 0.0525% (w/v) ammonium 
persulphate.
Samples containing approximately 50 fig protein were dialysed against a 
weak buffer when necessary, and incubated at 100°C with an appropriate volume 
of sample buffer [0.062 M Tris-HCl, pH  6 .8 , 1% (w/v) SDS, 50% (v/v) glycerol, 
10% (v/v) mercaptoethanol, 0.005% (w/v) bromophenol blue] for 1 minute.
Particles or precipitates in the sample were pelleted by centrifugation and 
the supernatant was loaded into a well in the stacking layer.
At least one lane contained unstained molecular weight markers (SDS-6 H)
in order to calibrate the gel:
Carbonic anhydrase (bovine erythrocytes) 29 kDa
Ovalbumin 45 kDa
Albumin (bovine plasma) 6 6  kDa
Phosphorylase B (rabbit muscle) 97.4 kDa
P-Galactosidase (£. coli) 116 kDa
Myosin (rabbit muscle) 205 kDa
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Samples were electrophoresed at 60 V for approximately 30 minutes or 
until the protein had entered the gel. The voltage was then increased to 2 0 0  V 
for approximately 5 hours. The electrophoresis buffer contained 0.025 M Tris- 
HCl, pH  8.3, 0.192 M glycine and 0.1% (w/v) SDS.
The gels were fixed and stained in 45% (v/v) methanol, 1 0 % (v/v) acetic 
acid, 0.1% (w/v) Coomassie Brilliant Blue R, and were subsequently destained in 
solution containing 5% (v/v) methanol and 7.5% (v/v) acetic acid.
Molecular weight estimation was made by comparison of the Rf value of 
the sample against a calibration curve of Rf against molecular weights of the 
molecular weight markers.
2.2.4 Western blot
In order to probe discrete electrophoretic bands with specific antibodies, proteins 
were transferred to nitrocellulose. The nitrocellulose (Bio-Trace NT; Gelman 
Sciences Ltd) was soaked in blot buffer, pH  8.3, comprising 0.025 M Tris,
0.192 M glycine, methanol 20% (v/v), before sandwiching with the SDS-PAGE 
gel and several thicknesses of absorbent paper. This was then placed in the blot 
tank (Bio-Rad Laboratories Ltd) containing blot buffer. Proteins were transferred 
with a constant voltage 30 V for 16 hours at 4°C.
The nitrocellulose was washed with three changes of PBS-T; free binding 
sites were blocked by incubation with PBS-T containing 1 % (w/v) casein for a 
minimum of 1  hour at room temperature.
The PBS-T/casein was discarded and the nitrocellulose was washed as 
before. The blot was incubated with the test antibody, diluted in PBS-T/casein,
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for 2-3 hours. The antibody solution was discarded and the nitrocellulose was 
washed. It was incubated with an appropriate volume of species- and isotype- 
specific, biotinylated antibody 0.1% (v/v) in PBS-T/casein (Vectastain ABC Kit, 
Vector Laboratories Ltd) for a minimum of 1 hour.
This antibody solution was discarded and the nitrocellulose was washed 
thoroughly. The blot was incubated for a minimum of 1 hour with PBS-T/casein 
containing pre-formed biotin-avidin HRP complexes 0.5% (v/v) (Vectastain ABC 
Kit).
The blot was washed with PBS-T and further washed with PBS. It was 
incubated in horseradish peroxidase (HRP) substrate, 0.5% (v/v) 4-chloro-l- 
naphthol [from stock 3% (w/v) in methanol] and 0.012% (v/v) hydrogen 
peroxide, in PBS, overnight at room temperature. The reaction was stopped by 
washing with PBS.
2.2.5 Spectrophotometric assay for total XOR activity (Avis et al,, 
1956)
The rate of urate production in aerated 0.05 M potassium phosphate, pH  8.3, 
with 104  M xanthine and 5xl04  M N A D + was followed spectrophotometrically 
at 295 nm.
The extinction coefficient for uric acid is 9.6 x 1 0 3 M^cm'1.
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2.2.6 Fluorescent assay for XOR activity 
(Beckman et al., 1989)
The sensitivity of this assay is two orders of magnitude greater than the 
spectrophotometric measurement of urate production. Pterin interacts with the 
enzyme at the same active site as xanthine. The enzyme catalyses the conversion 
of pterin to isoxanthopterin. Methylene blue acts as an electron acceptor allowing 
measurement of dehydrogenase activity.
Fluorescent measurement was made by a Perkin Elmer LS-5B fluorimeter 
with A,excitation 345 nm and A,emission 390 nm and slit width 5 nm. The assay buffer 
was 0.05 M potassium phosphate with 10' 5 M pterin for measurement of XOR 
activity. Methylene blue, 10'5 M, was added to the assay mixture to allow 
measurement of dehydrogenase activity. Xanthine oxidoreductase activity was 
inhibited with allopurinol 4x1 O'5 M. The assay was calibrated by addition of 
isoxanthopterin standards.
2.2.7 Screening ELISA for anti-(XOR) antibodies
Microtitre 96-well plates (Labsystems) were coated with either BXO or purified
H X O  in 0 . 1  M carbonate/hydrogen carbonate coating buffer, pH  9.6
( 1 0  /xg per ml, 1 0 0  [A per well) and incubated at room temperature for 2  hours or
overnight at 4°C.
The plates were washed extensively with PBS-T and the wells were 
blocked with 1 % (w/v) casein in PBS-T, 100 /xl per well for 1 hour at room 
temperature or at 4°C overnight. The PBS-T/casein was removed and the plates 
were washed as before. The test antibody fraction -  tissue culture supernatant or 
polyclonal antiserum -  was added to the wells and doubling dilutions were made
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across the plate, 1 0 0  (A per well. The plate was incubated for 2  hours at room 
temperature. After washing, the immobilized antilbody was incubated with 
species-specific donkey anti-(mouse or rabbit immunoglobulin) antibody 
conjugated with HRP (Amersham International pic), diluted 1 in 1000 in PBS-T 
( 1 0 0  /d per well) for 2  hours at room temperature. The plates were washed with 
PBS-T followed by PBS. Horseradish peroxidase saibstrate, 0 .0 0 1 % (w/v) 
tetramethyl benzidine [stock 10% (w/v) in dimethyl sulphoxide (DMSO)] and 
0.006% (v/v) hydrogen peroxide in 0.05 M citrate/acetate buffer, pH  6.0, was 
added to the wells and the colour reaction was slowed with 1.84 M sulphuric acid 
(50 (A per well). The absorbance at 450 nm was measured using the Dynatech 
plate reader. Normal cloning medium was used as the negative control when 
screening hybridoma supernatant; for polyclonal amtibody (pAb) screening, 
normal rabbit or mouse serum was used.
2.2.8 Coupling protein to cyanogen bromide-activated Sepharose
Biological molecules can be partially or wholly purified from a heterogeneous 
mixture by exploiting ligand/receptor affinities. By immobilizing either ligand or 
receptor on a gel or solid matrix, a re-usable affinity column can be constructed. 
This method of protein coupling was used to prepare HXO, BXO, protein A 
and monoclonal antibody (mAb) affinity columns (H2C2).
Cyanogen bromide-activated (CNBr) Sepharose 4B (Pharmacia Biotech 
Ltd) was suspended in 0.001 M HCl (200 ml), swilled gently and then left to 
swell for 15 minutes. The gel was washed on a sintered funnel with 0.001 M HCl 
(600 ml), distilled water (600 ml), and 0.1 M sodium hydrogen carbonate buffer,
54
pH  8.3 (600 ml). The protein to be coupled was dialysed against several changes 
of coupling buffer, 0.1 M sodium hydrogen carbonate buffer, pH  8.3, containing 
0.5 M sodium chloride.
The protein was added to the gel at a ratio of 1 0  mg per ml swollen gel 
(3 g Sepharose 4B swelled to approximately 10 ml) when coupling protein A, and 
5 mg protein per ml gel for all other proteins. The ligand and gel were tumbled 
end-over-end for 1 2  hours at 4°C. With HXO, the tumbling period was increased 
to 48 hours.
After coupling, the gel was centrifuged at 300 g for 10 minutes; the 
supernatant containing uncoupled ligand was retained for protein estimation. The 
gel was washed twice with coupling buffer, by dispersion and centrifugation The 
remaining active groups on the matrix were initially blocked with 0.2 M Tris, 
pH  8.0, for 2 hours, but this resulted in protein leaching from the Sepharose.
The protocol was modified and 1  M ethanolamine, pH  8 .0 , was used to block the 
active sites. The gel was washed with 3 cycles of alternating pH  (i.e. 0.1 M 
sodium acetate, pH  4.0, containing 0.5 M sodium chloride followed by 0.1 M 
Tris, pH  8.0, containing 0.5 M sodium chloride. The column was washed with 
PBS and stored in PBS containing 0 .0 2 % (w/v) sodium azide at 4°C.
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2.2.8.1 Preparation of BXO affinity columns
Commercially available BXO (Biozyme Laboratories), 20 mg, was coupled with 
CNBr-activated Sepharose 4B at a ratio 5 mg per ml swollen gel (Materials and 
Methods 2.2.8).
Coupling efficiency was 85-93%, determined by estimation of uncoupled 
protein in the gel washes. The affinity matrix was packed in a column of suitable 
dimensions.
2.2.8.2 Preparation of HXO affinity columns
Construction of a column similar to that described for BXO, with 10 mg HXO, 
was attempted (Materials and Methods 2.2.8.1). The human enzyme was 
obtained from human breast milk (Appendix II). With 12 hours end-over-end 
mixing, coupling efficiency was low (i.e. less than 2 0 % determined by estimation 
of uncoupled protein in the gel washes). On increasing the duration of mixing to 
48 hours, the efficiency increased to 70%.
2.2.8.3 Preparation of protein A affinity columns
Protein A, 20 mg, was attached to CNBr-activated Sepharose at a ratio of 
10 mg per ml swollen gel (Materials and Methods 2.2.8).
Coupling efficiency with this ligand was approximately 90% determined 
by estimation of uncoupled protein in the gel washes.
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2.3 Antibody production, purification and labelling
2.3.1 Production of pAb
2.3.1.1 Immunization
Healthy rabbits were immunized with either 100 /-ig HXO purified from breast 
milk, or 100 /*g BXO with an equal volume of alum adjuvant (Pierce).
Booster injections of the same immunogen were given 3-4 weeks later.
Ten days after this, a small volume of blood was withdrawn from the rabbit and 
tested by a screening ELISA (Materials and Methods 2.2.7) to ensure that an 
immune response had been provoked.
If the immunization had been successful (i.e. titre >  3 x 104), a further 
boost was given 3-4 weeks later. Approximately 20-30 ml blood was collected by 
bleeding the ear vein 10 days after the booster immunization. Subsequent boosts 
and bleeds were continued for 6  months.
2.3.1.2 Preparation of antiserum
The collected blood was allowed to stand at room temperature for 30 minutes. 
Using a scalpel or spatula, the clot was squeezed and chopped. The blood was left 
to stand at room temperature for a further 30 minutes, after which time it was 
centrifuged at 2500 g for 1 0  minutes. The serum was collected and stored at - 
20°C. Under these conditions, the polyclonal IgG was stable for at least 
6  months.
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2.3.2 Purification of pAb
2.3.2.1 Purification of IgG from antiserum
The clarity of the antiserum (V ml) was checked. If the sample was turbid, it was 
centrifuged at 2500 g for 15 minutes. Saturated ammonium sulphate solution 
(100%) was added to the antiserum, drop wise with constant stirring, to give 45% 
saturation. Stirring was continued for 15 minutes. After 30 minutes’ 
centrifugation at 3000 g, the supernatant was discarded and the precipitate was 
redissolved in V/ 2  ml 0 . 2  M Tris-HCl, pH  8.0.
Saturated ammonium sulphate solution was added to the redissolved 
precipitate, dropwise with constant stirring, to give 40% saturation. Again, 
stirring was continued for 15 minutes and the precipitate was collected following 
centrifugation. The clean, white precipitate was redissolved in V/5 ml 
0.03 M phosphate buffer, pH  7.3, and dialysed over 24 hours against two changes 
(5 1 each) of the phosphate buffer.
The ammonium sulphate precipitation was followed by crude ion- 
exchange chromatography. A small column was packed with diethylaminoethyl- 
cellulose (DE-52; Whatman Ltd) equilibrated with 0.03 M phosphate buffer, 
pH  7.3. The column was washed thoroughly with the phosphate buffer, and the 
IgG preparation was loaded onto the column and eluted with phosphate buffer. 
Contaminants were eluted with the starting buffer and 0.5 M NaCl.
Although this method was used to obtain IgG in early 
experiments, it was later replaced by protein A-affinity chromatography 
(Materials and Methods 2.3.2.2).
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23.2.2 Protein  A-affinity purification of IgG from  polyclonal antiserum  
When a crude fraction of IgG was required, the high affinity of protein A 
(isolated from Staphylococcus aureus) for the Fc region of IgG was exploited. 
Protein A was immobilized on cyanogen bromide-inactivated Sepharose 4B as 
described previously (Materials and Methods; Section 2.2.8).
The pH  of the antiserum was adjusted to 8.0 with 1  M Tris, pH  8.0. 
Antiserum was slowly recycled through a 4 ml protein A-Sepharose column, 
previously equilibrated with 0 . 0 1  M Tris, pH  8.0, overnight at 4°C.
The gel was washed with 0 . 1  M Tris, pH  8 .0 , and then with 0.01 M Tris, 
pH  8.0. The bound IgG was eluted with 0.1 M glycine, pH  3.0. Eluted fractions 
were collected in tubes containing 1/20 fraction volume 1 M Tris, pH  8 .0 . 
Fractions were pooled and dialysed against two changes of PBS.
2.3.2.3 BX O /H X O -affinity purification of polyclonal Ig from  antiserum
Frozen antiserum was thawed at room temperature.
The chosen affinity column was equilibrated with either 0.01 M Tris 
buffer, pH  7.5, or PBS. The chromatography apparatus comprised peristaltic 
pump, UV monitor (UV-1), control unit (UV-1 ), chart recorder and fraction 
collector (Frac-1 0 0 ) in a dedicated system (Pharmacia Biotech Ltd). The A 280 of 
the eluate was monitored and recorded.
Antiserum was diluted 1 in 10 in 0.1 M Tris, pH  7.5, or PBS, depending 
on the choice of equilibrating buffer, and recycled slowly through the column 
overnight at 4°C.
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The column was washed extensively with the equilibrating buffer, and 
then with the same buffer containing 0.5 M sodium chloride. Bound antibodies 
were eluted with a cycle of low and high pH. Elution with 0.1 M glycine-HCl, 
pH  2.5, was followed by washing with 0.01 M Tris, pH  8 .8 , until the pH  of the 
column reached 8 .0 . This was followed by elution with 0.05 M diethylamine, 
pH  11.5. The column was then washed with 10 mM Tris, pH  7.5, or PBS, and 
stored in 0.02% (w/v) sodium azide. Fractions containing antibody eluted at low 
pH  were collected in tubes containing 1/20 fraction volume 1 M phosphate 
buffer, pH  8.0; fractions containing antibody eluted at high pH  were collected in 
tubes containing 1/20 fraction volume 1 M phosphate buffer, pH  6 .8 .
The fractions were pooled according to pH  of elution, dialysed against 
several changes of PBS and stored at either 4°C or with glycerol, 1 : 1  (v/v), 
at -2 0 °C.
This protocol was subsequently simplified for the purification of anti- 
(BXO) antibodies on a BXO-affinity column. In this case, antibodies were eluted 
with 0.05 M diethylamine, pH  11.5, only; low pH  did not appear to elute any 
antibodies. In contrast, when elution from an H X O  affinity column was partially 
successful, bound proteins were eluted at both high and low pH.
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2.3.3 Production of mAb
2.3.3.1 Normal cloning media
RPMI 1640 media (ICN Biomedicals Ltd) 
containing sodium hydrogen carbonate ( 2  g /1)
Foetal calf serum (FCS), heat inactivated 
(Myoclone Plus; Gibco BRL) 10% (v/v)
Anti-PPLO agent (Gibco BRL) 1% (v/v)
L-glutamine (Gibco BRL) 0.002 M
Later batches included
Penicillin/streptomycin (Gibco BRL) 100 IU /m l
Batches of media were autoclaved at 2 0  lb /in 2 for 30 minutes and, after cooling 
to room temperature, were either used immediately or stored at -20°C for up to 
6  months.
2.3.3.2 Immunization
Balb/c mice were immunized with 10-100 jug H XO from breast milk (Appendix 
II), with an equal volume of alum adjuvant.
Initially, an identical booster was given 3-4 weeks later, though later 
immunization schedules were altered to allow boosting 6 - 1 0  weeks after the 
initial immunization. A blood sample from the tail tip was taken 10 days after 
the boost and was tested by ELISA (Materials and Methods 2.2.7). If the anti- 
(XOR) titre was high compared with normal mouse serum, a final boost of 10 /*g 
H X O  with an equal volume of alum was given 3-4 weeks (or 6-10 weeks, in 
later schedules) after the second boost and the fusion was carried out 5 days later.
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2.3.3.3 Myeloma cell line culture
Three weeks prior to the fusion, X-63 8 Ag myeloma cells were continuously 
grown and sub-cultured. The cells were grown in cloning medium containing
0.13 mM 8 -azaguanine before storage at -70°C and, on thawing, were grown in 
normal cloning medium and tested at intervals for aminopterin sensitivity. The 
cells were sub-cultured every 2-3 days in order to maintain log-phase growth.
2.3.3.4 Provision of a macrophage feeder cell layer
Macrophage feeder cell layers were prepared 1 - 2  days prior to the fusion. Balb/c 
mice were killed by cervical dislocation; fur and skin were sterilized by 
immersion in 70% ethanol. The skin was dissected back to expose the 
peritoneum. Sterile PBS (5 ml) was injected into the peritoneal cavity of each 
mouse. Mouse abdomens were massaged for several minutes to suspend the 
peritoneal macrophages in the PBS. These were then withdrawn by a pipette 
inserted through a hole cut in the peritoneum.
The macrophage suspensions were irradiated for 4 minutes ( 2 0 0 0  rads) and 
pelleted by centrifugation, 1 0  minutes at 300 g. The supernatant was discarded 
and the cells were resuspended in a small volume of normal cloning medium. A 
cell count was performed and the macrophages were diluted to a suitable volume 
in cloning medium containing hypoxanthine, aminopterin and thymidine (HAT 
supplement) and seeded out in 96-well tissue culture plates (Falcon; Becton 
Dickinson Ltd) at approximately 20,000 per cm2.
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2.3.3.5 Fusion procedure and subsequent growth of hybridomas
Polyethylene glycol (PEG 4000; Serva), 4.5 g, was added to 5.5 ml PBS, pH  7.4, 
in a McCartney bottle. This was autoclaved and agitated while still hot to fully 
dissolve and disperse the PEG. The temperature of the PEG/PBS was maintained 
at 37°C until needed.
The immunized mouse was killed by cervical dislocation and the spleen 
was removed and transferred to a 90 mm Petri dish (Bibby Sterilin Ltd). The 
spleen cells were washed out with sterile PBS (10 ml) injected repeatedly into the 
spleen sac. The cells were transferred to a sterile tube and further dispersed by 
gentle trituration. The cell suspension was allowed to stand for a few minutes 
and any connective tissue settled out. The cells were transferred to a sterile glass 
centrifuge tube (50 ml).
The myeloma cells were harvested and approximately 2  x 1 0 7 cells were 
added to the glass centrifuge tube. A mouse spleen contains approximately 1 0 8 
splenocytes and the ratio of myeloma cells to splenocytes in this fusion 
procedure was 1:5.
The mixed cells were centrifuged at 300 g for 1 0  minutes. The supernatant 
was discarded and the warm PEG/PBS solution ( 1  ml) was added, dropwise, over 
60 seconds to the pellet, with constant agitation to prevent the cells clumping. 
This was immediately followed by adding warm PBS (1 ml) in the same manner. 
Further warm PBS was added slowly to reach a final volume of 2 0  ml. The cells 
were centrifuged as before, resuspended in warm normal cloning medium ( 2 0  ml) 
and transferred to a 50 ml sterile flask. The flask was incubated at 37°C overnight 
to allow completion of the fusion process.
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The next morning the cells were centrifuged for 1 0  minutes at 300 g, and 
resuspended in cloning medium (100 ml) containing HAT supplement. The cells 
were dispensed into five macrophage-conditioned plates, 2 0 0  /d per well. The 
plates were incubated at 37°C (1 0 % C 0 2 in air) for 5 days.
The medium was replenished at day 5 by withdrawal of medium (150 /xl) 
and replacement with fresh HAT medium (175 /d). After a further 5 days, the 
medium was similarly replenished with cloning medium supplemented with H T 
only. At day 15, the cells were again fed with H T medium.
Colonies appeared 2-3 weeks after the fusion and the supernatants were 
screened. Cells secreting antibodies positive on ELISA (Materials and Methods 
2.2.7) were cloned.
2.3.3.6 Cloning by limiting dilution
The cells in a selected well were counted for viability and serially diluted in fresh 
normal cloning medium until the theoretical concentration was 1 0 0  cells per 
15 ml. This volume of cells was dispensed over a freshly macrophage-conditioned 
96-well plate (150 /d per well) giving an approximate theoretical ratio of 1 cell 
per well. The plates were incubated under normal conditions.
The screen/clone procedure was carried out three times after which the 
cell line was deemed to be monoclonal.
O n several occasions, no hybridoma colonies formed following the first 
cloning stage. The initial cloning dilutions were subsequently altered to give 
theoretical ratios of 1 cell/well in 24 wells, 10 cells/well in 24 wells, 100 
cells/well in 24 wells and 1000 cells/well in 24 wells. Cells from healthy colonies
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at the lowest dilution were then grown up and cloned three times as previously 
described.
Monoclonal cell lines were established and the supernatant harvested at 
intervals; the supernatant was screened regularly to ensure antibody secretion had 
not stopped. Stocks were stored at -70°C.
2.3.3.7 Freezing hybridomas
Cells were carefully resuspended in the supernatant and centrifuged at 300 g for 
1 0  minutes. Supernatant was removed and cells were resuspended in normal 
cloning medium ( 1  ml) and transferred to a 2  ml sterile cryogenic vial (Imperial 
Laboratories Ltd). The vial was placed on ice for 15 minutes. An equal volume of 
ice-cold freezing mixture [50% (v/v) FCS, 30% (v/v) RPMI 1640, 20% DMSO 
(v/v)] was added and the vial was mixed by inversion. The sealed vial was placed 
in the vapour phase of a liquid nitrogen storage vessel and was cooled at 
approximately 1°C per minute to -70°C. After 24 hours, the vial was fully 
immersed in the liquid nitrogen.
2.3.3.8 Thawing hybridomas
Cell lines were recovered from liquid nitrogen and rapidly defrosted by 
incubating the vials in a water bath at 37°C. The cells were washed with two 
changes of normal medium and returned to normal culture conditions.
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2.3.4 Monoclonal antibody isotype ELISA
Rows of the microtitre plate were coated as indicated (Table 6 ). The 96-well 
microtitre plate was coated with 10 ^g/m l BXO or HXO, or 1/1000 dilution 
isotype specific goat anti-(mouse Ig) antibody. The plate was incubated for 
2  hours at room temperature, or 12 hours at 4°C.









Table 6 . Antibodies used to coat the microtitre plate for monoclonal isotype 
ELISA.
66
The plate was washed thoroughly with PBS-T and free, non-specific 
binding sites were blocked by incubation with 1% (w/v) PBS-T/casein for 1 - 1 2  
hours.
After further washing, test hybridoma supernatants were added,
1 0 0  /d/well, 1  supernatant/plate column. The plate was incubated for 2  hours at 
room temperature.
The wells were washed and incubated with donkey anti-(mouse Ig) 
antibody conjugated with HRP (Amersham International pic) for 2 hours.
The plate was washed and further rinsed with PBS; HRP substrate,
0.001% (w/v) tetramethyl benzidine [stock 10% (w/v) in DMSO] and 0.006%
(v/v) hydrogen peroxide in 0.05 M citrate/acetate buffer, pH  6.0, was added to 
the wells and the colour reaction was slowed with 1.84 M sulphuric acid (50 /d 
per well). The absorbance at 450 nm was measured using the Dynatech plate 
reader.
2.3.5 Antibody labelling
2.3.5.1 Biotinylation of antibodies (Vector Laboratories* recommended 
protocol)
Biotin (long arm) N-hydroxysuccinimide ester (Vector Laboratories) was 
dissolved in DMSO, to give a final concentration between 25 and 50 mg/ml. The 
protein to be biotinylated, IgG or IgM at approximately 10 mg/ml, was dialysed 
against two changes of 0.1 M sodium hydrogen carbonate buffer, pH  8.5. 
Biotinylating reagent, 10% (w/w), was added dropwise to the protein solution. 
This was incubated, with gentle stirring, for 2  hours at room temperature. The
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reaction was stopped by adding 10 mg glycine. Unreacted biotin was removed by 
extensive dialysis against PBS or by gel filtration through a 9.1 ml Sephadex 
G-25 M column (PD-10). Biotinylated antibody was stored at -20°C, 1:1 (v/v) 
with glycerol.
2.3.5.2 Determination of biotin/protein ratio (modified from Green, 1965)
A solution containing avidin 0.65% (w/v) in 0.02 M potassium phosphate buffer, 
pH  7.0 was prepared. The same buffer was used to prepare 0.005 M 
4-hydroxyazobenzene benzoic acid (HBA). Avidin solution was carefully mixed 
with HBA in a cuvette at a ratio of 45:1. The absorbance was measured at 
500 nm spectrophotometrically (Pye Unicam SP6-450 UV/VIS 
spectrophotometer; Philips). Samples ( 2  /d) of the biotinylated protein were 
added and the corresponding decrease in absorbance was determined. The assay 
was calibrated using sequential 1  /d additions of a standard biotin solution 
(0.20 mg/ml in 0.001 M sodium hydroxide).
This assay was also scaled down and carried out on a microtitre plate to 
conserve the biotinylated antibody.
A typical calibration curve is shown for this assay (Figure 8 ). Using this 
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Figure 8. A sample reference curve for biotin/protein ratio determination using a method modified 
from Green (1965)
2.4 Cross-linking antibodies to protein A
Protein A was coupled to cyanogen bromide-activated Sepharose as described 
previously (Materials and Methods 2 .2 .8 ).
Rabbit affinity-purified anti-(BXO) pAb was mixed with the protein A gel 
( 2  mg antibody per ml wet beads). The gel was incubated with the antibodies at 
room temperature for 1  hour with gentle rocking. The beads were washed twice 
with large volumes of 0 . 2  M sodium borate, pH  9.0, by centrifugation at 300 g 
for 1 0  minutes.
The beads were resuspended in the borate buffer, and enough 
dimethylpimelimidate was added to bring the final concentration to 20 mM. This 
suspension was gently rotated for 30 minutes at room temperature. The reaction 
was stopped by washing the beads in 0.2 M ethanolamine, pH  8.0, centrifuging 
and incubating for 2  hours in the same solution, at room temperature. The gel 
was washed in PBS and stored in PBS with 0.02% sodium azide at 4°C.
Elution of bound enzyme from this gel was with 0.05 M diethylamine, 
pH  11.5, containing 0.5 M sodium chloride. Fractions containing protein were 
collected in 1/20 volume 1  M phosphate buffer, pH  6 .8 . The gel was washed 
with 20 column volumes of 10 mM phosphate buffer, pH  8.0, between elutions.
2.5 Homogenization of animal and human tissue
N.B. Suitable precautions were taken when handling human postmortem tissue. 
All work was carried out in a Class II extraction hood, designated for use with 
human material.
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Fresh or deep frozen tissue (thawed at room temperature) was chopped 
into small pieces. Tissue, 25% (w/v) in distilled water containing 
4 mM dithiothreitol and protease inhibitors, leupeptin, antipain, aprotinin and 
pepstatin A (all at 1 /d/ml), was homogenized on ice. The crude homogenate was 
buffered with x 5 PBS, 1 0 % (v/v) and centrifuged at 35,000 g for 30 minutes at 
4°C. The pellet was discarded and finely ground ammonium sulphate was added 
to the supernatant ( 2 0  g/ 1 0 0  ml). The suspension was stirred at 4°C for 
10 minutes and then centrifuged at 15,000 g for 30 minutes at the same 
temperature. The pellet was discarded and further ammonium sulphate was added 
to bring the final concentration to 40 g/ 1 0 0  ml. The suspension was stirred and 
centrifuged as before.
The pellet was suspended in PBS containing DTT and protease inhibitors 
as described for the homogenization solution, and dialysed against several changes 
of this PBS over 24 hours. The dialysed supernatant was filtered through a series 
of disposable filter units, 1.2 /im to 0.22 /nm (Millipore UK Ltd) and used 
immediately.
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2.6 Purification and activity of aldehyde oxidase
2.6.1 Purification of aldehyde oxidase from rabbit liver (Warne 
and Stell, 1990)
Fresh rabbit liver was homogenized, 25% (w/v) in ice-cold 0.067 M phosphate 
buffer, pH  7.8. The homogenate was incubated at 55°C for 10 minutes and 
rapidly cooled in an ice bath.
The cooled homogenate was centrifuged at 15,000 g for 45 minutes at 4°C. 
The pellet was discarded and finely ground ammonium sulphate was added,
40 g/ 1 0 0  ml. The suspension was stirred slowly in an ice bath for 2 0  minutes; 
the precipitated protein fraction was collected by centrifugation at 6000 g for 
20 minutes at 4°C.
The pellet was resuspended in homogenization buffer ( 1  ml/ 1 0  g original 
weight) and then equilibrated with Buffer A (0.1125 M glycine-NaOH, pH  9.0 
with 0.1125 M sodium chloride, 10-4 M EDTA and 0.002 M cysteine), either by 
dialysis or gel filtration (Sephadex G-25M; PD-10).
A 5 ml p-aminobenzamidine-Sepharose 6 B column was equilibrated with 
Buffer A. Crude homogenate was recycled through the column for 12 hours at 
4°C. The column was washed with Buffer A until the A436 of the eluate returned 
to baseline (benzamidine absorbs at 280 nm). Bound protein was eluted with 
Buffer B (Buffer A with 0.006 M benzamidine).
Eluted fractions with positive A436 were pooled and precipitated with 65% 
(w/v) ammonium sulphate followed by centrifugation at 6000 g for 2 0  minutes. 
The pellet was resuspended in 100 [A Buffer A, injected onto a Superose 6  gel
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filtration column (FPLC: Pharmacia Biotech Ltd), and eluted with 0.05 M bis- 
Tris propane-HCl, pH  7.2 containing 1  x 104  M EDTA and 2  x 10'3 M cysteine.
The fraction containing protein was determined from the UV A 280 trace 
and injected onto a Mono Q  anion exchange column. Elution with a linear 
sodium chloride gradient (0-35% in 0.02 M bis-Tris propane-HCl, pH  6.9 
containing 5% (v/v) betaine and 2 x 10'3 M cysteine) was unsuccessful and the 
protein could not be retrieved from the column.
Fractions from different stages in the purification method were analysed 
by SDS-PAGE (Materials and Methods 2.2.3) and assayed for XOR and aldehyde 
oxidase activity (Materials and Methods 2.2.5, 2.6.2).
From visual interpretation of the SDS-PAGE pattern, it appeared that gel 
filtration and anion exchange chromatography were unnecessary for the purity 
required and were omitted from later purifications.
The purification was repeated and the fractions were tested by anti-(BXO) 
capture ELISA (Results 3.2.2.3) and Western Blot with IgM anti-(XOR) mAb 
(Materials and Methods 2.2.4).
2.6.2 Spectrophotometric assay for aldehyde oxidase activity (Stell 
et al., 1989)
The rate of p-dimethylaminocinnamaldehyde oxidation by aldehyde oxidase was 
measured spectrophotometrically. The assay mixture comprised 
p-dimethylaminocinnamaldehyde 2.5 x 10'5 M in 0.067 M potassium phosphate 
buffer, pH  7.0; the reaction was monitored at 398 nm. The extinction coefficient 
for the substrate at 398 nm is 3.05 x 104 M^cm'1.
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3 Results
3.1 Antibody production, purification and labelling
NB Titre values correspond to the dilution of antibody preparation at which 
absorbance is half maximum, and are expressed numerically as the reciprocal of 
that dilution.
3.1.1 Polyclonal antibody preparation
Two rabbits, coded 117 and 124, were immunized with H X O  prepared from 
human breast milk (Appendix IQ; rabbit coded 118 was immunized with BXO. 
Stocks of antisera from previously immunized rabbits (Dr A Rogers), were also 
available.
A sample of blood was withdrawn from the rabbit 10 days post­
immunization, from which antiserum was prepared (Materials and Methods
2.3.1.2). This was tested by ELISA against H X O  and/or BXO, immobilized on 
microtitre plates (Materials and Methods 2.2.7). Figure 9 shows typical titration 
curves from two ELISAs, one with 10 jug/ml BXO immobilized on the 
microtitre plate and the other with 1 0  /xg/ml HXO immobilized on the 
microtitre plate. As a negative control, normal rabbit serum (NRS) was also 
tested on each plate. The titres from these ELISAs are summarized in Table 7.
Both H X O  and BXO were found to be highly immunogenic in rabbits, 
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Titre x 1 0 4 9.09 6.67 0.026 58.8 2.78 0.048
Table 7. Antisera titration curves from rabbits designated 117 and 118 compared; 
one microtitre plate was coated with 10 jug/ml BXO and the other with 1 0  
pig/ml HXO.
3.1.1.1 Purification of IgG from antiserum
Ammonium sulphate precipitation followed by crude ion-exchange 
chromatography (Materials and Methods 2.3.2.1) yielded 6 - 8  mg IgG per ml 
antiserum. Being relatively time-consuming, however, this method was soon 
replaced by protein A purification (Materials and Methods 2.3.2.2).
3.1.1.2 Protein A purification of IgG from antiserum
Buffered antiserum was recycled through a protein A column and bound IgG was 
eluted with 0.1 M glycine pH  3.0 (Materials and Methods 2.3.2.2). Approximately
0.1 g IgG was routinely prepared from 1 0  ml antiserum.
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3.1.1.3 Affinity purification of anti-BXO antibodies
Antiserum, diluted 1  in 10 in 0.1 M Tris, pH 7.5, or in PBS, depending on the 
choice of buffer used to equilibrate the affinity column, was recycled slowly 
through the BXO affinity column overnight at 4°C. Elution with cycles of high 
and low pH  buffers (Materials and Methods 2.3.2.3) yielded negligible protein at 
low pH  and was, therefore, replaced by single-step elution with 0.05 M 
diethylamine only. Affinity purification using BXO gel routinely yielded 
10-18 mg polyclonal antibody from 20 ml anti-(BXO) antiserum, on elution with
0.05 M diethylamine (Table 8 ; Figure 10).
Affinity-purified anti-(BXO) pAb was used to probe BXO and H X O  on 
Western blots (Materials and Methods 2.2.4). Photograph 1 shows an SDS-PAGE 
gel and subsequent detection pattern achieved with affinity-purified anti-(BXO) 
pAb (from rabbit 118 in this case) and denatured HX O  and BXO. As expected, 
the BXO lanes show strong staining, with major bands staining at Mw 136, 126, 
99, 64 and 43 kDa and many minor bands also staining. There was also cross­
reaction with HXO, with major enzyme bands at 141 and 136 kDa showing 
strongest staining, and further detection at 225, 194, 104, 71 and 61 kDa.
In addition, BXO affinity-purified anti-(BXO) pAb had higher titres 
against BXO than H XO in ELISA (Materials and Methods 2.2.7). Examples of 
curves and titres are shown (Figure 1 1 ; Table 9).
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Elution cycle
Total protein in eluted fractions
(mg)
Rabbit 78 Rabbit 78 Rabbit 79 Rabbit 79 Rabbit 118 Rabbit 118
1 5.1 5.5 11.7 9.3 4.3 6.8
2 3.0 3.1 4.4 6.1 4.8 5.4
3 1.8 2.0 0.9 2.3 3.2 2.9
4 - 0.8 - 0.5 1.2 0.6
Total 9.9 11.4 17.0 18.2 13.5 15.8
Table 8 . Antiserum (20 ml) from rabbits immunized with BXO (rabbit identification number indicated) was 
recycled through a 10 ml BXO affinity column. Bound protein was eluted with 0.05 M diethylamine, pH  11.5. The 
unadsorbed fraction was recycled and the elution was repeated until it was estimated that negligible anti-(BXO) 
antibody remained in the unadsorbed fraction.
T  3rd  e lu tio n  T  2nd e lu tion  T  U nadsorbed  recycled T  1st e lu tion
T U nadsorbed  recycled








Photograph 1. Western blot with affinity-purified rabbit anti-(BXO) polyclonal 
antibodies (118 at 50 /xg/ml) and corresponding SDS-PAGE gel.
1 . HXO (Western blot)
2. BXO (Western blot)
3. BXO (Western blot)
4. BXO (SDS-PAGE)
5. HXO (SDS-PAGE)
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Figure 1 1 . Titration curves of affinity-purified anti-(BXO) pA b from  rabbit 118 against tw o preparations of H X O  from  
breast m ilk (H X O  preparation 1, H X O  preparation 2), com mercially available BXO  (BXO 1) and BX O  prepared from  














1.92 x 102 5.88 x 102 3.12 x 103 8.3 x 103
Table 9. Titres of affinity-purified anti-(BXO) pAb from rabbit 118 against two 
preparations of H X O  from breast milk (HXO preparation 1 ,
H X O  preparation 2 ), commercially available BXO (BXO 1) and BXO prepared 
from fresh bovine milk in the laboratory (BXO 2 ).
3.1.1.4 Affinity purification of anti-H XO antibodies
Affinity purification of anti-(HXO) pAb using an HXO affinity column was less 
efficient than anti-(BXO) pAb purification using a BXO affinity column (Results
3.1.1.3). Enzyme breakdown appeared to cause rapid deterioration of the affinity 
column as evidenced by the following experiment.
Beads were removed from the HXO affinity column after one attempted 
purification (i.e. 5 days after column preparation). These were subjected to SDS- 
PAGE (Materials and Methods 2.2.3) using a ‘minigel’ system (Bio-Rad 
Laboratories Ltd). Although, using this system, the band resolution is poor, the 
enzyme appeared to have broken down to fragments running with Mw 
approximately 96, 82, 63 and 31 kDa (Photograph 2 ). Protein bands 
corresponding to H X O  monomers (Mw — 150 kDa) are absent from the gel. A 
comparison lane shows BXO from a BXO affinity column that had been 
prepared a month previously and used to affinity purify several batches of
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antiserum. In this case, the band pattern characteristic of BXO is retained, 
though some lesser degree of breakdown does appear to have occurred. A typical 
H X O  breakdown pattern on storage at 4°C for 5 days is shown (Photograph 3 ) 
The instability and paucity of purified H X O  made routine preparation 
and use of H X O  affinity columns impractical. Results from the two purifications 
performed are presented, however (Table 1 0 ).
Photograph 4 shows a Western blot with a batch of affinity-purified anti- 
(HXO) pAb (rabbit 117) and HXO. The enzyme (lane 3) had been purified (i.e. 
post-gel filtration stage, refer to Appendix IQ approximately 1 0  days prior to use 
and showed a pattern of enzyme breakdown on SDS-P AGE. Although the 
antibodies detected bands at around 140-125, 80 and 75 kDa, strongest staining 
occurred at bands corresponding to approximately 53-57 and 25-27 kDa.
The antibodies were also used to detect proteins in a sample of crude 
H X O  [i.e. post-ammonium sulphate precipitation stage, refer to Appendix II 
(lane 1)]; the staining pattern is similar to that of the purified HXO, with bands 
at 140, 136, 80, 56 and 27 kDa.
A sample of a non-HXO protein often copurifying with the enzyme and 
running with a molecular weight of 80 kDa was included in this blot [(lane 2 ) see 
also Results 3.3.4.2]. Although detection of protein running with this molecular 
weight occurred with both the crude and purified HXO, staining of this band 
was very weak.
83
H X O  affinity-purified anti-(HXO) pA b had similar titres against BX O and 
H X O . Figure 12 shows titra tion  curves of affinity-purified anti-(H X O ) pA b from  
rabbit 117 against tw o preparations of H X O  from  breast m ilk (H X O  preparation 
1, H X O  preparation 2), commercially available BX O  (BXO 1) and BX O  
prepared from  fresh bovine m ilk in the laboratory (BXO 2). Titres are





sum m arized in Table 11.
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Photograph 2 . Com parison of H X O  
rem oved from  H X O -affinity colum n at day 
5 after preparation, w ith BXO removed 
from  a BXO-affinity colum n at day 30 after 
preparation.
1. BX O  removed at day 30




Photograph 3. C om parison  of freshly 
purified H X O  w ith  H X O  at day 5 
after preparation.
1. M olecular weight m arkers
2. Freshly purified H X O
3. H X O  at day 5 after preparation
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Eluent Cycle Total protein in eluted fractions (mg)
Rabbit 117 Rabbit 124
0.1 M glycine, pH  2.5 1 2 . 1 1 . 6
0.05 M diethylamine, pH  11.5 1 1.5 0.9
0.1 M glycine, pH  2.5 2 2.7 1 . 2
0.05 M diethylamine, pH  11.5 2 0.3 0.5
0.1 M glycine, pH  2.5 . 3 0.5 negligible
0.05 M diethylamine, pH  11.5 3 negligible negligible
Total 7.1 4.2
Table 10. Antiserum ( 1 0  ml volumes) from rabbits immunized with H X O  (rabbit identification number indicated) were recycled 
through 10 ml H X O  affinity columns. Bound protein was eluted with 0.1 M glycine, pH  2.5, and 0.05 M diethylamine, 
pH  11.5. The unadsorbed fraction was recycled and the elutions were repeated until it was estimated that negligible anti-(HXO) 
antibody remained in the unadsorbed fraction.
Mw (kDa)
1 2  3 4 5 6  7  8 9 1 0 1 1  12
P h o to g ra p h  4. SDS-P A GE gel and corresponding W estern b lo t w ith  
affinity-purified rabbit anti-(HX O) polyclonal antibodies (117 at 50 jxg/ml).
1. Partially purified H X O  (SDS-P AGE)
2. 80 kD a contam inant (SDS-PAGE)
3. Purified H X O  at 10 days after preparation (SDS-P AGE)
4. M olecular weight markers (SDS-PAGE)
5-7. Purified H X O  at 10 days after preparation (Western blot)
8-9. 80 kD a contam inant (W estem blot)




















- HXO preparation 1 
HXO preparation 2 
A- - BXO  1 
■A—  BXO 2
0.1 0.01 0.001 0.0001 0.000011
Stock antibody dilution
Figure 1 2 . T itration curves of affinity-purified anti-(HXO) pAb from  rabbit 117 against tw o preparations of H X O  from  breast 
m ilk (H X O  preparation 1, H X O  preparation 2), commercially available BXO (BXO 1) and BXO prepared from  fresh bovine 











BXO 2  
(in-house 
preparation)
4.54 x 103 2.94 x 103 3.22 x 1 0 3 5.88 x 103
Table 11. Titres of affinity-purified anti-(HXO) pAb from rabbit 117 against two 
preparations of HX O  from breast milk (HXO preparation 1, H XO preparation 
2), commercially available BXO (BXO 1) and BXO prepared from fresh bovine 
milk in the laboratory (BXO 2).
3.1.2 Monoclonal antibody production
A mouse was immunized with H XO (Materials and Methods 2.3.3.2 ), and 
antiserum, obtained 1 0  days post-immunization, was diluted and titrated across a 
microtitre plate coated with BXO or HXO (Materials and Methods 2.2.7). An 
example of a titration curve is shown (Figure 13; titre = 5.55 x 103).
After several immunization boosts, judged successful by ELISA titre 
(i.e >  5 x 1 0 3), the immunized mouse was sacrificed by cervical dislocation. The 
fusion procedure for hybridoma production was followed (Materials and Methods 
2.3.3.5); healthy hybridoma colonies were screened for anti-(XO) Ig production, 
by the standard ELISA (Materials and Methods 2.2.7), and class tested (Materials 
and Methods 2.3.4).
Hybridoma supernatants with anti-(XOR) activity, judged by ELISA end 
product (A450 >  0.2 above reference blank) indicated cell lines for expansion and 
cloning. The monoclonal cell lines established are summarized in Table 1 2 .
Photographs 5 and 6  show a typical SDS-P AGE band pattern for HXO 
and BXO, and Western blot detection pattern using an anti-(XOR) mAb (2G3 in 
this case). All the monoclonal antibodies raised cross-reacted with H XO and 



























0.1 0.01 0.001 0.0001 0.00001 0.000001
A ntiserum  dilution factor
Figure 13. ELISA com paring the anti-BXO titration  curves of antiserum from  a mouse im m unized w ith  BXO w ith  norm al 
mouse serum.
H y b rid o m a Im m unogen Ig class an ti-H X O anti-B X O
*H3G7 H X O IgM + +
*B5B4 BXO IgM + +
*H2C2 H X O IgG - -
2A3 H X O IgM + +
2G3 H X O IgM + +
Table 12. Five hybridom a cell lines secreting monoclonal antibodies were 









12  3 4 5 6
P h o to g ra p h  5. SDS-P AGE band patterns 
for H X O  and BXO.
1. Partially purified H X O
2. Purified H X O
3. BXO
4. M olecular weight markers
P h o to g rap h  6. C orresponding 
W estern blot, using supernatant 
from  cell line 2G3.
1-3. Partially purified H X O  
4-6. BXO
91
Four fusions were attempted prior to those resulting in the establishment of 
hybridoma lines 2A3 and 2G3. O n the first two occasions, the primary fused 
cells became infected and were discarded. As a result, antibiotics 
(penicillin/streptomycin 100 IU/ml; Materials and Methods 2.3.3.6 ) were added 
to all batches of cloning medium.
O n the subsequent two occasions, hybridomas resulted from the fusion 
but did not survive the first cloning. The initial cloning procedure was 
subsequently modified (Materials and Methods 2.3.3.6 ).
3.1.3 Determination of the H2C2 antigen
Supernatant from the hybridoma line H2C2 did not show positive staining on 
Western blot analysis, though it did have a titre comparable with that of the 
other anti-(XOR)-positive supernatants on HXO ELISA (i.e. ~50). In order to gain 
information about H2C2 recognition, an affinity chromatography column was 
constructed with the monoclonal antibody as the ligand.
Solid ammonium sulphate was added to H2C2 supernatant to give 45% 
saturation. The solution was stirred for 30 minutes at room temperature and 
centrifuged at 3000 g for 30 minutes. The supernatant was discarded and the 
pellet was resuspended in 0.1 M sodium hydrogen carbonate buffer, pH  8.3, 
containing 0.5 M sodium chloride to give a final concentration of ~ 5  mg/ml. The 
solution was dialysed against two changes of 0 . 1  M sodium hydrogen carbonate 
buffer, pH  8.3, containing 0.5 M sodium chloride.
The dialysed mAb solution was coupled with CNBr-activated Sepharose 
(Materials and Methods 2.2.8), packed into a small column and equilibrated with
92
PBS. Crude HX O  (post-ammonium sulphate precipitation; Appendix II) was 
exchanged into PBS via gel filtration using a 9.1 ml Sephadex G-25 M column 
(PD-10; Pharmacia Biotechnology Ltd) and a sample ( 1  ml) was loaded onto the 
H2C2 affinity column. After washing with PBS, bound protein was eluted with 
0.05 M diethylamine containing 0.5 M NaCl, pH  11.5. The diethylamine-eluted 
fraction was exchanged into PBS via gel filtration, assayed for H XO activity 
(Materials and Methods 2.2.5) and subjected to SDS-P AGE (Materials and 
Methods 2.2.3).
The gel and subsequent Western blot with HXO-affinity-purified anti- 
(HXO) pAb are shown in an earlier section (Photograph 4, Results 3.1.1.4). The 
diethylamine-eluted fraction comprised an 80 kDa protein, with a trace of 
protein running with molecular weight approximately 140 kDa. On Western blot 
with HXO-affinity-purified pAb, the 80 kDa band stained very weakly. The 
H XO activity of the eluted fraction was negligible as determined by 
spectrophotometric assay.
H2C2 supernatant was tested by ELISA against the enzyme stock used to 
immunize the parent mouse (stored at -20°C: HXO 1) and a newer enzyme stock 
prepared using a modified purification protocol (HXO 2 ; Appendix II). The 
results are shown (Figure 14). The H2C2 titre against H XO 1 is comparable with 
that of the other (IgM) mAb-secreting hybridoma supernatants (45). However, 























Hi— HXO 1 (Immunogen)
■- - HXO 2 (Purified using modified protocol)
1 0.1 0.01 0.001 0.0001 0.00001
Supernatant dilution factor
Figure 14. T itration  curves of H2C2 supernatant against the enzyme stock used to  im m unize the parent mouse (H X O  1) and a 
new er enzym e stock prepared using a modified purification protocol (H X O  2; A ppendix II).
3.2 Development of ELISA to measure HXO and BXO
One of the main aims of this project was to develop a method of quantifying 
X O R protein in biological mixtures. Different ELISAs were attempted, using 
either the anti-(XOR) IgM mAb or the anti-(XOR) pAb. It was hoped that, on 
establishment of a workable assay, monoclonal IgGfs) could be substituted for 
the monoclonal IgM or polyclonal IgG.
3.2.1 Inhibition ELISA
By their nature, the anti-(XOR) IgM monoclonal antibodies were more specific 
than the anti-(XOR) polyclonal antibodies (compare Photographs 1 and 4 with 
Photograph 6 ). These antibodies were, therefore, first choice for use in an 
ELISA.
As a result of their pentameric nature, IgM antibodies do not, in general, 
coat microtitre plates effectively. An ELISA was designed using BXO as the plate 
coat; mAb was incubated with the test sample, which contained BXO, and then 
titrated across the microtitre plate. The difference between absorption with and 
without incubation with test sample related to antigen in the test sample. Again, 
the pentameric nature of IgM required that the amount of antibody in the 
incubation mixture be kept minimal so that saturation of paratopes was possible. 
Suitable dilutions of H3G7 were determined empirically to be between 1/500 and 
1/ 1000.
Microtitre 96-well plates were coated with BXO in 
0.1 M carbonate/hydrogen carbonate coating buffer, pH  9.6, (5 /xg per ml, 100 [A 
per well) and incubated at room temperature for 2  hours or overnight at 4°C .
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The plates were washed thoroughly with PBS-T and non-specific protein-binding 
sites were blocked by incubation with PBS-T/casein ( 2  hours).
During this time, a range of volumes of anti-(HXO) mAb H3G7 was 
mixed with a constant volume of BXO and the antigen/antibody mixtures were 
allowed to stand for 1  hour.
The microtitre plates were washed and 1 0 0  (A aliquots from each mixed 
and incubated sample were titrated (doubling dilutions) across the plate. As a 
positive control, aliquots from mixtures with PBS in place of BXO were titrated 
across the plate; as a negative control, samples of BXO at the same concentration 
(v/v) as in the BXO/mAb mixtures were also titrated across the plates.
The plates were incubated at room temperature for 2  hours, and then 
washed thoroughly with PBS-T. Wells were incubated with species-specific 
goat anti-(mouse Ig) Ig/HRP conjugate (Amersham International pic) at stock 
dilution 1 / 1 0 0 0 , 1 0 0  /d per well for 2  hours at room temperature.
Plates were washed thoroughly with PBS-T and rinsed with PBS. 
Horseradish peroxidase substrate -  0.05 M citrate/acetate buffer, pH  6.0, with 
0.001% (w/v) tetramethyl benzidine [stock 10% (w/v) in DMSO] and 0.006% 
(v/v) hydrogen peroxide -  was added to the wells and the colour reaction was 
slowed with 1.84 M sulphuric acid (50 /d per well). The absorbance at 450 nm 
was measured as described previously.
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By altering the length of antigen-antibody incubation and the amount of 
BXO immobilized on the microtitre plate, it was possible to detect a range of 
BXO concentrations (Figure 15). However, because the IgM antibodies were of 
low affinity (Appendix III), only very shallow reference curves were achieved. As 
useful reference curves in ELISA should not extend beyond a 2 to 3 log scale 
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Figure 15. Sample calibration curve with BXO, using the anti-(BXO) inhibition ELISA, n=8.
3.2.2 Capture ELISAs for the detection of BXO and HXO
3.2.2.1 Combining monoclonal and polyclonal antibodies
A successful capture ELISA requires that the primary and detector antibodies 
recognise different antigen epitopes. A heterogeneous pAb population is likely to 
recognise a variety of epitopes, in contrast to a mAb population which is 
homogeneous in nature. As the mAbs were murine in origin, and the pAbs were 
obtained from immunized rabbits, it was possible to combine these in a capture 
ELISA, using a species-specific, enzyme-labelled tertiary antibody as detector.
Affinity-purified anti-(BXO) polyclonal antibody was immobilized on the 
microtitre plate (5 jug/ml). Three stock solutions of BXO in PBS (50 /xg/ml,
5 /xg/ml and 0.5 /xg/ml) were titrated across the plate (doubling dilutions) in 
duplicate. As a negative control, PBS replaced the BXO in a further row 
(negative control 1); the final row had dilution from 50 /ng/ml BXO for 
subsequent incubation with PBS in place of secondary antibody 
(negative control 2 ).
The wells were all incubated with B5B4 (1/1000 dilution in PBS), except 
the control row (negative control 2), which was incubated with PBS. After 
washing, the wells were incubated with species-specific goat anti-(mouse) Ig 
conjugated with HRP, adsorbed against rabbit Ig (Amersham pic). Subsequent 
steps are as described in Materials and Methods 2.2.7.
All wells developed high background coloration, except those in the 
control row (negative control 2 ), and there was no significant difference between 
results obtained using no antigen (negative control 1) and those with BXO at 
50 jug/ml. This indicated that an association between the primary and secondary
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antibody was occurring. The coloration could not be due to recognition between 
tertiary and primary antibody as it did not occur in the absence of the secondary 
antibody (negative control 2 ).
Similar high background values occurred when the mAb was used to coat 
the plate, and the pAb was used as secondary antibody [with species-specific goat 
anti-(rabbit) antibody conjugated with HRP as tertiary antibody]. However, in 
this case, titration curves with BXO diluted from 50 /xg/ml and 5 /xg/ml were 
achieved (Figure 16).
From these results it appeared that either the pAb was cross-reacting with 
the mAb, or native antigen was associated with the affinity-purified pAb, causing 
high background in the absence of BXO in the assay mix.
As the sensitivity of the assay could not be improved below around 
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Figure 16. Sample curves w ith BXO, using a m A b/pA b capture ELISA. 
M onoclonal antibody B5B4 was used to  coat the plate, and anti-(BXO) pAb was 
used as secondary antibody [with species-specific anti-(rabbit) antibody conjugated 
w ith H R P as tertiary  antibody].
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3.2.2.2 Using IgM mAbs
Although the similarities in behaviour between the different IgM mAbs 
indicated that they recognised the same epitopes, it seemed a worthwhile exercise 
to try to incorporate two different mAb populations into a capture ELISA.
Both H3G7 and B5B4 were biotinylated (Materials and Methods 2.3.5.1 ). 
Non-biotinylated H3G7 was used to coat the plate, while biotinylated B5B4 was 
used as the detector, and vice versa. Streptavidin (or later, as a cheaper alternative, 
Extravidin) conjugated with HRP was used in place of the tertiary antibody 
conjugate described previously (Results 3.5.2.1).
N o coloration above background was achieved using either combination. 
This was most probably the result of recognition of the same epitopes by the 
different IgM antibodies, though inefficient coating of the microtitre plate and 
low affinity of both IgM lines could be contributing factors.
As the ‘sticky’ Fc portions of the IgM molecule are not exposed, IgM 
antibodies coat microtitre plates less well than IgG antibodies. In order to expose 
the Fc portions and, hence, make the coating antibody more ‘sticky’, 
fragmentation (reduction followed by gel filtration; Johnstone and Thorpe, 1990) 
was attempted. However, coating the plate with IgM fragments did not improve 
the assay, and coloured end-point was not achieved.
Similarly, coating the microtitre plate with goat anti-(mouse IgM) 
antibody prior to incubation with the IgM fraction, did not affect the results.
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3.2.2.3 Using polyclonal antibodies only
As neither of the IgM mAbs investigated appeared suitable for incorporation in 
to an ELISA, investigation of the less desirable pAb/pAb capture ELISA was 
made. By incorporating a label in one fraction of the antibody, this fraction can 
be used as the detection antibody with the same antibody, non-labelled, used as 
the capture antibody. Subsequent detection is via the label.
The following assay used a biotin label attached to IgG prepared from 
anti-pCOR) antiserum, in conjunction with affinity-purified anti-(XOR) antibody 
from the same batch of antiserum. Detection is via streptavidin or Extravidin 
conjugated to HRP.
Once a high-affinity, IgG mAb has been established, it could then be 
substituted for the biotinylated (secondary) polyclonal IgG fraction.
Polyclonal IgG was prepared from anti-(BXO) antiserum using protein A 
chromatography (Materials and Methods 2.3.2 .2 ). Approximately half of the IgG 
prepared was then passed through a BXO affinity column, yielding affinity- 
purified anti-(BXO) IgG (Results 3.1.3). The non-specific polyclonal IgG fraction 
was biotinylated (Materials and Methods 2.3.5.1) to give 6-7 biotin labels/IgG 
molecule).
Microtitre plates were coated with affinity-purified anti-(BXO) pAb 
( 1 0  jug/ml; 100 fA per well) for 1 2  hours at 4°C or 2  hours at room temperature. 
The wells were washed with PBS-T and incubated with 1% (w/v) PBS-T/casein 
for 1 hour at room temperature. The test sample, PBS with BXO, was incubated 
in the wells for 2  hours at room temperature. The wells were washed and 
incubated with biotinylated pAb, diluted to an empirically determined optimum
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dilution in PBS-T ( 1 0 0  f A  per well), for 2  hours at room temperature. The wells 
were washed and incubated with streptavidin or Extravidin, conjugated to HRP, 
diluted 1 in 1000 in PBS-T, (100 fx 1 per well), for 1  hour at 37°C. The wells were 
washed with PBS-T and PBS. Horseradish peroxidase substrate -  0.05 M 
citrate/acetate buffer, pH  6.0 with 0.001% (w/v) tetramethyl benzidine [stock 
1 0 % (w/v) in DMSO] and 0.006% (v/v) hydrogen peroxide -  was added to the 
wells and the colour reaction was slowed with 1.84 M sulphuric acid (50 fA per 
well). The absorbance at 450 nm was measured as described previously (Materials 
and Methods 2.2.7).
The graph from this ELISA was approximately linear between 6  and 
14 ng BXO (Figure 17). The sensitivity of the assay was slightly extended by 
substituting Extravidin-alkaline phosphatase for Extravidin-HRP (Figure 18). 
After incubation with Extravidin-alkaline phosphatase, p-nitrophenyl phosphate 
( 2 0 0  f A / well) was added for approximately 30 minutes. The colour reaction was 
slowed with 3 M sodium hydroxide, and the absorbance of each well at 405 nm 
was measured spectrophotometrically. However, as the enzyme label did not 
make a significant difference, and HRP reagents were commonly used in-house, 





















B X O  (ng)
12 14 16
Figure 17. Calibration curve for BXO using a pAb/pA b capture ELISA with the 
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Figure 18. Calibration curve for BXO using a pA b/pA b capture ELISA with the 
biotin/avidin-alkaline phosphatase detection system, n=8.
By substituting anti-(HXO) IgG -  affinity purified and non-specific -  for 
anti-(BXO), detection of HXO in PBS was achieved (Figure 19). It is interesting 
to note that substituting HXO for BXO in the ELISA using anti-(BXO) IgG was 
unsuccessful, with no end-point coloration being achieved. This was probably 
due to the lower affinity of these antibodies for the human enzyme.
Initial standard curves achieved in this ELISA could not, however, be 
reproduced using later batches of antibodies. High, uniform end-stage coloration 
resulted, even in the absence of XOR. As the two antibody phases were prepared 
from the same batch of antibody, anti-(idiotope) reaction was unlikely. It 
appeared, therefore, that antigen was present, in excess amounts, in the assay. 
Simple gel filtration of a batch of affinity-purified antibody indicated that the 
polyclonal antibodies existed in two states (Figure 20). From the results of the 
















7 81 2 3 4 5 6
H X O  (ng)
Figure 19. Calibration curve for HXO using a pA b/pA b capture ELISA with the 
biotin/avidin-HRP detection system, n=8.
m<N
Figure 2 0 . Gel filtration trace (UV detection at 280 nm) showing, on the basis of size, two distinct populations of 
pAb existed in a standard preparation from antiserum.
3.3 Partial purification of BXO and HXO
As mouse anti-(BXO/HXO) monoclonal IgG would be of potential use in 
purifying the enzyme from heterogeneous mixtures, preliminary experiments 
were designed using rabbit affinity-purified anti-(BXO) pAb.
Rabbit anti-(BXO) pAb, affinity purified against BXO, were cross-linked 
to protein A/Sepharose 4B using dimethylpimelimidate (Materials and Methods 
2.4). Efficiency of cross-linking was assessed by determining the protein content 
of the gel washes. Several gels were prepared and the efficiency of coupling was 
70-85%.
3.3.1 Extraction of BXO from BXO in solution
The matrix was packed into a 3 ml column and pre-elution with PBS and 
0.5 M sodium chloride was performed to remove weakly bound protein. A 
solution of BXO in PBS (5 ml at 0.5 mg/ml) was slowly recycled through the 
column for 12 hours at 4°C. After washing with 20 column volumes of 
10 mM phosphate buffer, pH  8.0, bound enzyme was eluted with 
0.05 M diethylamine, pH  11.5, containing 0.5 M sodium chloride. Fractions 
containing protein were collected in 1/20 volume 1 M phosphate buffer, pH  6 .8 . 
Approximately 1  mg BXO was eluted from the column. The binding capacity of 
the column was, therefore, approximately 1 mg BXO/5 mg immobilized 
polyclonal IgG.
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3.3.2 Partial purification of BXO from bovine milk
A crude preparation (i.e. post-ammonium sulphate precipitation) of bovine 
enzyme from fresh milk was provided (J Khan). The sample, 0.5 ml with total 
XOR activity 3.5 ± 0.23 nmoles/minute/mg, was applied to the anti-(BXO) 
IgG/protein A/Sepharose 4B affinity column. It was slowly recycled through the 
gel for 8 - 1 2  hours at 4°C. The gel was washed with 1 0  mM phosphate buffer, pH 
8 .0 , until the A 2S0 trace had returned to baseline (i.e. zero non-specific protein 
elution).
Bound protein was eluted with 0.05 M diethylamine containing 
0.5 M sodium chloride. The unadsorbed fraction was recycled through the washed 
matrix and a second bound peak was eluted. Eluted fractions were collected in 1/20 
volume 1 M phosphate buffer, pH  6 .8 .
The peaks were pooled, concentrated, exchanged into PBS and assayed, 
spectrophotometrically, for total XOR activity (Materials and Methods 2.2.5). The 
spectrophotometric assay was repeated five times, and the total BXO activity of 
the eluted fraction was found to be 14.5 ± 1 nmoles/minute/mg. Thus, active 
bovine enzyme can be eluted from the column under the conditions described.
The experiment was repeated and the eluted bound fractions were pooled, 
concentrated and visualized by SDS-PAGE. The gel showed the bound protein 
with a double band at approximately 150 kDa, characteristic of the XOR, with a 
minor band at approximately 80 kDa.
I l l
3.3.3 Extraction of ‘HXO-like’ protein from human milk
The experiment described previously was repeated with a crude preparation of 
human milk (i.e. post-ammonium sulphate precipitation; D Powell). The sample 
(1 . 0  ml), was slowly recycled through the gel for 8 - 1 2  hours at 4°C. The gel was 
washed with 10 mM phosphate buffer, pH 8.0, until the A2S0 trace had returned to 
baseline (i.e. zero non-specific protein elution), and bound protein was eluted with
0.05 M diethylamine containing 0.5 M sodium chloride. Eluted fractions were 
collected in 1/20 volume 1 M phosphate buffer, pH 6 .8 .
The eluted bound fractions were pooled, concentrated, exchanged into PBS 
and visualized by SDS-PAGE (Photograph 7). There is no trace of 80 kDa 
contaminant in the eluted fractions, though a faint band corresponding to a 
molecular weight of approximately 40 kDa could be seen on the gel. The binding 
capacity of the column for partially purified HXO was approximately 0.15 mg (i.e. 
15% binding capacity for BXO).
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Photograph 7. SDS-PAGE gel showing partial purification of H X O  from  hum an 
m ilk using the anti-(BXO) affinity column.
1. C rude H X O
2. U nadsorbed fraction
3-6. Adsorbed fraction (at different loading concentrations)
7. BXO
8. M olecular weight markers
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3.3.4 Partial purification of BXO from bovine liver
Fresh bovine liver was obtained from an abattoir and stored at -70°C, for 
1-6 months. Samples were thawed at room temperature when needed.
A portion (12 g) was thawed at room temperature and roughly chopped 
in to small pieces. Tissue, 25% (w/v) in distilled water containing 4 mM 
dithiothreitol and protease inhibitors -  leupeptin, antipain, aprotinin and 
pepstatin A (all at 1  /d/ml), was homogenized on ice. The crude homogenate was 
buffered with concentrated (x 5 normal PBS), 10% (v/v), and centrifuged at 
35,000 g for 30 minutes at 4°C.
The pellet was discarded and finely ground ammonium sulphate was 
added to the supernatant at 2 0  g/ 1 0 0  ml. The suspension was stirred at 4°C for 
10 minutes and then centrifuged at 15,000 g for 30 minutes at the same 
temperature. The pellet was discarded and further ammonium sulphate was added 
to bring the final concentration to 40 g/ 1 0 0  ml. The suspension was stirred and 
centrifuged as before.
The pellet was suspended in PBS containing DTT and protease inhibitors 
as described for the homogenization solution, and dialysed against several changes 
of this PBS over 24 hours. The dialysed supernatant was filtered through a series 
of disposable filter units, 1.2 finl to 0.22 fim (Millipore UK Ltd) and used 
immediately.
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The anti-(BXO) IgG/protein A gel was equilibrated with PBS. The crude 
bovine liver preparation was buffered with 1 / 1 0  volume concentrated 
(x 5 normal) PBS.
The liver preparation was slowly recycled through the affinity column 
overnight. Unbound and weakly bound protein was washed from the gel with 
PBS and then PBS containing 0.5 M sodium chloride. Bound protein was eluted 
with 0.05 M diethylamine containing 0.5 M sodium chloride. Fractions were 
collected in tubes containing 1/20 volume concentrated (x5) PBS. Pooled 
fractions were concentrated, exchanged into PBS and assayed for total BXO 
activity (Materials and Methods 2.2.5; Table 13).
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Fraction N um ber of 
assays
(n)
Mean BXO activity 
(nmoles/ m inute/m g)
% CV
Crude 2 1.25 7.5
Adsorbed 3 33.5 2 . 6
Unadsorbed 2 0.51 8.9
Table 13. Bovine liver fractions were assayed spectrophotometrically for BXO 
activity.
Samples of the crude, unadsorbed and bound fractions were run on 
SDS-gel (Photograph 8 ). A Western blot was performed on the bound fraction 
using the anti-(BXO) mAb, B5B4, and affinity-purified anti-(BXO) pAb 
(Photograph 9). For this blot, pAb was detected using an alkaline phosphatase 
system and mAb was detected using the HRP system. The results are summarized 
in Table 14.
Both polyclonal and monoclonal antibody recognized bands corresponding 
to molecular weights 129-150 kDa, indicating that these bands are BXO protein. 
The molecular weights of bands running further down the gel suggest that these 
might be the heavy and light chains of polyclonal anti-(BXO) antibody stripped 
from the affinity column during elution. However, as the polyclonal anti-(BXO)
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antibody in the Western blot was detected with goat anti-(rabbit) IgG, these bands 
would have been expected to stain darkly if this was the case. In fact, the band 
corresponding to 51-63 kDa showed only very light staining that is not consistent 
with this scenario.
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Photograph 8 . SDS-PAGE gel 
showing fractions from anti-(BXO) 
affinity purification using bovine liver 
homogenate.





Photograph 9. Corresponding Western 
blot using anti-(BXO) pAb at 30 ^g/ml, 
and supernatant from the cell line B5B4. 
1 , 2 . BXO (B5B4)
3, 4. Adsorbed fraction (B5B4)
5. BXO (pAb)
6 . Adsorbed fraction (pAb)
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Band Detected by 
monoclonal antibody
Detected by polyclonal 
antibody
150 kDa / /
141 kDa / ✓
129 kDa / /
51-63 kDa X Faint
27 kDa X X
24 kDa X X
Table 14. Blotting the bound peak with monoclonal and polyclonal anti-(BXO) 
antibody showed similar patterns.
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3.3.5 Visualization of ‘HXO-like’ protein in three human tissues
Homogenates of human smooth muscle, heart and liver (removed at post-mortem 
and deep frozen at -70°C for up to 6  months) were prepared as described 
previously (Results 3.6.4). Samples from each homogenate were subjected to SDS- 
PAGE followed by Western blotting using a multi-antibody approach (modified 
from Lee et al., 1988).
After staining with Ponceau S [0 .0 2 % (v/v) in 3% trichloroacetic acid; 
Photograph 1 0 ], the blot was cut into two halves. One half of the blot was 
probed with the anti-(BXO) IgM mAb, B5B4, and the Vectastain (HRP) 
detection system (Photograph 11). The other half was probed with a mixture of 
affinity-purified anti-(BXO) pAb and the anti-(HXO) mAb, 2A3 (Photograph 1 2 ). 
The pAb was detected using HRP-conjugated, species-specific, goat anti-(rabbit) 
IgG and diaminobenzidine, which gave brown bands. The mAb was detected 
using alkaline-phosphatase-conjugated, species-specific, goat anti-(mouse) IgM and 
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Sigma Fast™ 
BCIP/NBT buffered substrate tablets), which gave dark blue bands. Bands 
recognised by both antibodies were characterized by brown/black staining, 
which was not as dark as NBT only. It was, therefore, easy to distinguish 
between protein bands recognised by the different antibodies. As the coloured 
bands are not easy to distinguish from Photograph 12, the results of molecular 
weight estimation of bands recognised are presented in Tables 15-17.
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In addition to probing homogenates immobilized on nitrocellulose, small 
samples of homogenate were passed through the anti-(BXO) affinity column as 
described previously (Results, 3.3.4). Adsorbed protein was eluted with 0.05 M 
diethylamine, pH  11.5, containing 0.5 M sodium chloride. The sequential elution 
traces for smooth muscle, heart and liver are presented (Figure 21). Protein peaks 
adsorbed by anti-(BXO) pAb, and eluted at pH  11.5, were observed for the three 
tissues. Heart fraction contained less protein and, hence, the elution profile 
differed from those of smooth muscle and liver.
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Photograph 10. Ponceau S-stained nitrocellulose blotted against crude human 
smooth muscle, liver and heart homogenates on an SDS-PAGE gel.
1 , 2, 8 , 9. Human smooth muscle 
3, 4, 1 0 , 1 1 . Human heart 
5, 6 , 1 2 , 13. Human liver 
7, 14. HXO
15. Molecular weight markers
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1 2 3 4 5 6 7
Photograph 11. Western blot using supernatant from the cell line B5B4 against 
crude human smooth muscle, liver and heart homogenates.
1, 2. Human smooth muscle
3, 4. Human heart
5, 6 . Human liver
7. HXO
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Photograph 12. Western blot using supernatant from the cell line 2A3, and 
affinity-purified anti-(BXO) pAb, against crude human smooth muscle, liver and 
heart homogenates.
1, 2. Human smooth muscle
3, 4. Human heart


































Table 16. Interpretation of the m ulti-antibody W estern blot w ith crude hum an 























Sm ooth muscle recycled : : ; V L i - i  tI. . . I  .  i. _  g .  i i T Heart recycled t  Heart elution  
T Smooth muscle elution
T Liver recycled T Liver elution
Figure 21. Elution profile of hum an smooth muscle, heart and liver from  the anti-(BXO) affinity colum n, using
0.05 M diethylamine, p H  11.5, containing 0.5 M sodium chloride, as eluant.
3.3.6 Partial purification of ‘HXO-like’ protein from human liver
Samples of human liver, removed at post-mortem, were deep frozen at -70°C for 
up to 6  months.
A portion (wet weight 3.8 g) was removed and thawed at room 
temperature. Crude homogenate was prepared by blade homogenization, 
ammonium precipitation, centrifugation and pellet dialysis, as described 
previously (Results 3.6.4). The dialysed supernatant was filtered through a series 
of disposable filter units, 1 . 2  /xm to 0 . 2 2  /xm and used immediately.
The anti-(BXO) IgG/protein A gel was equilibrated with PBS. The crude 
human liver preparation was buffered with 1 / 1 0  volume concentrated 
(x 5 normal) PBS.
The liver preparation was slowly recycled through the affinity column 
overnight. Unbound and weakly bound protein was washed from the gel with 
PBS and then PBS containing 0.5 M sodium chloride. Bound protein was eluted 
with 0.05 M diethylamine containing 0.5 M sodium chloride; fractions were 
collected in tubes containing 1/20 volume x 5 PBS. Fractions containing bound 
protein were pooled, concentrated, exchanged into PBS and assayed for total 





N um ber of 
assays
(n)
Total H X O  activity 
(nmoles/ m inute/m g)
%CV
Crude 1 1 0 3 3.7 1 0 . 8
Adsorbed 0.40 3 6 . 8 18.7
Unadsorbed 56 4 13.0 2 1 . 2
Table 18. Crude human liver preparation was recycled through the anti- 
BXO/protein A affinity column. Fractions were assayed spectrophotometrically 
for total XOR activity.
The reason for the seemingly nonsensical results for the unadsorbed 
fraction is unclear. While the protein content appears to have diminished by 
nearly 50%, the XOR activity is almost double that of the crude fraction.
Samples from each stage were run on SDS-PAGE (Photograph 13). The 
lane with bound protein (lane 8 ) showed bands corresponding to molecular 
weights 141 kDa, 129 kDa, 89 kDa, 65 kDa, 53 kDa.
Photograph 14 shows the greatly increased number of bands that occurred 
when protease inhibitors were omitted from the protocol.
As a comparison, human liver homogenate was passed through a 
heparin-agarose column similar to that used for purification of HX O  from milk 
(Appendix II). Elution conditions were similar to those used for milk enzyme, 
with bound proteins eluted with stepwise increases in ionic strength of the 
eluent. In milk preparations, HXO elutes with 0.4 M sodium chloride and, 
indeed, a peak similar to HXO (in terms of estimated molecular weight) was seen
130
in the 0.4 M eluate (running with Mw=147 kDa; pure HXO runs with Mw=143 
and 129 kDa on the same gel). The ‘129-kDa-like’ band was not detectable in the
0.4 M eluate, but a similar double band pattern was seen in the crude lane 
(i.e. bands running at Mw=147 and 135 kDa). The four major bands eluting with
0.4 M sodium chloride corresponded to Mw=56, 50, 43 and 34 kDa. In addition, 
bands also occurred corresponding to molecular weights below 29 kDa 
(Photograph 15).
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1 2 3 4 5 6 7  8 9
P h o to g ra p h  13. SDS-PAGE gel showing anti-(BXO)-pAb-adsorbed fraction 
extracted from  hum an liver homogenate.
1. M olecular weight markers
2. BX O  
3-6. H X O
7, 8. A dsorbed fraction from  hum an liver homogenate
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P h o to g ra p h  14. SDS-PAGE gel showing anti-(BXO)-pAb-adsorbed fraction 
extracted from  hum an liver homogenate in the absence of protease inhibitors.
1. M olecular weight markers
2. U nadsorbed fraction
3. C rude hum an liver homogenate
4. Adsorbed fraction
5. C rude fraction





P h o to g rap h  15. SDS-PAGE gel showing fractions obtained from  hum an liver 
homogenate using heparin chrom atography.
1. M olecular weight markers
2. H X O
3. Eluant = sodium phosphate buffer containing 1 M sodium  chloride
4. Eluant = sodium phosphate buffer containing 0.4 M sodium  chloride
5. Eluant = sodium phosphate buffer containing 0.1 M sodium  chloride
6. Crude fraction
7. H X O
8. M olecular weight markers
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3.3.7 Partial purification of ‘HXO-like’ protein from human heart
Two samples of post-mortem human heart were deep frozen at -70°C for 2  
months, and then thawed at room temperature.
Crude homogenate was prepared by blade homogenization, ammonium 
precipitation, centrifugation and pellet dialysis, as for bovine liver (Results 3.6.4). 
The dialysed supernatant was filtered through a series of disposable filter units, 
1 . 2  /xm to 0 . 2 2  /xm and used immediately.
The anti-(BXO) IgG/protein A gel was equilibrated with PBS, and crude 
human heart preparation was buffered with 1 / 1 0  volume concentrated 
(x 5 normal) PBS.
The heart preparation was slowly recycled through the affinity column 
overnight at 4°C. Weakly bound protein was washed from the gel with PBS 
followed by PBS containing 0.5 M sodium chloride. Bound protein was eluted 
with 0.05 M diethylamine containing 0.5 M sodium chloride; fractions were 
collected in tubes containing 1/20 volume x 5 PBS.
Fractions containing bound protein were pooled, concentrated, exchanged 
into PBS. The experiment was repeated several times, and fractions were either 
assayed for HX O  activity or subjected to SDS-PAGE and Western blotting. 
Because of the small amounts of protein obtained on elution with 0.05 M 
diethylamine and 0.5 M sodium chloride, it was not possible to assay the same 
enzyme peak for activity and visualize the proteins on SDS-PAGE.
Photograph 16 shows the band pattern of protein eluted from the anti- 
(BXO) column with one sample of human heart homogenate. The bands 
correspond to the following molecular weights, expressed in kDa: 139 (faint
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staining), 92, 70, 60, 47 (strong staining), 43, 27, <  27 (strong staining). Bands 
corresponding to the approximate position of the intact HX O  monomer did not 
occur. Fractions obtained from another sample of human heart homogenate were 
probed with the anti-(HXO) mAb 2A3. On this occasion, the preceding 
electrophoresis was stopped at an earlier stage, so that bands corresponding to 
lower molecular weights could be visualized more easily. With Ponceau S (i.e. 
non-specific protein) staining, the bands corresponding to bound protein ran with 
approximate Mw 6 6  and 30 kDa (Photograph 17). The anti-(HXO) mAb 
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P h o to g rap h  16. SDS-PAGE gel showing anti-(BXO)-pAb-adsorbed fraction 
extracted from  hum an heart homogenate.
1. M olecular weight markers
2. BXO
3. H X O
4. Crude hum an heart homogenate
5. Adsorbed fraction
6. U nadsorbed fraction
7. M olecular weight markers
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Photograph 17. Ponceau S-stained 
nitrocellulose blotted against hum an 
heart homogenate fractions show n on 
Photograph 16.
1. Crude hum an heart homogenate
2. Adsorbed fraction
3. H X O
Photograph 18. W estern blot using 
supernatant from  the cell line 2A3, 
against hum an heart homogenate 
fractions show n on Photograph 17.
1. Crude hum an heart homogenate
2. Adsorbed fraction
3. H X O
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Fractions obtained from further human liver and heart preparations were 
run on the same SDS-polyacrylamide gel (Photograph 19). Bands corresponding 
to Mw 55 and <  29 kDa were evident for the adsorbed fractions of both liver 
and heart. The adsorbed fraction from heart had additional, faintly staining bands 
corresponding to 146, 106 and 39 kDa; the absence of these bands in the liver 
fraction, however, may simply reflect the lower amount of protein loaded onto 
the gel.
Total XOR and XO activity was measured using the fluorescent assay 
(Materials and Methods 2.2.6; Table 19). The addition of allopurinol to the assay 
mix inhibited the production of isoxanthopterin (Figure 22). The unadsorbed 
fractions had negligible XOR activity (Figure 23).
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1 2 3 4 5  6 7 8  9 10 11
P h o to g ra p h  19. SDS-PAGE gel showing anti-(BXO)-pAb-adsorbed fractions 
extracted from  hum an heart and liver homogenates.
1, M olecular weight markers
2, HXO
3, 6. C rude hum an heart homogenate
4, 7. A dsorbed fraction from  heart
5, 8. U nadsorbed fraction from  heart
9. C rude hum an liver homogenate
10. A dsorbed fraction from  liver
11. U nadsorbed fraction from  liver
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Sample 1 Sample 2
Tissue wet weight (g) 25.5 10.3
Crude protein (mg) 798 372
Unadsorbed protein (mg) 680 359
Bound protein (mg) 2.26 4.05
Mean X O R  activity of unadsorbed fraction negligible negligible
Mean XO activity of bound protein and 
%CV (pm oles/m in/m g)
3.02
(n -2 ; CV-14%)
4.10
(n=9; CV=28%)
Mean X O R activity of bound protein and 
%CV (pm oles/m in/m g)
3.9
(n -2 , CV=36%)
5.30
(n=6; CV=22%)
Table 19. Two human heart preparations were recycled through the anti-BXO/protein A affinity column. 
The fractions were assayed fluorimetrically for XOR and XO activity.
2 4Tim e (minutes) t^   ^ n in y ic ; | -f- a |
i W ith  hum an  h eart hom ogenate
lopurinol
Figure 22. The effect of allopurinol on the rate of isoxanthopterin form ation by 
an anti-(BXO) affinity-purified fraction from human heart homogenate.
'Fr 0  
EH ;"5i
1 t-t 1 Ct 1 i
T im e (m inutes)
T Rate with unadsorbed fraction
Figure 23. The unadsorbed fraction from anti-(BXO) affinity-purification of 
hum an heart homogenate had a negligible rate of isoxanthopterin form ation.
3.3.8 XOR activity in rat tissue
In order to compare data from fluorimetric analysis of enzyme activity 
determined in-house with published data, samples of rat heart and rat liver were 
homogenized and assayed under the same conditions as the human tissue samples. 
Results are presented (Table 20).
Reproducibility was poor between the assays, and results appear to be 
significantly lower than those reported in the literature (see Discussion 4.7).
Liver H eart
W et weight (g) 6.11 0.98
Homogenate protein (mg) 409 37
Mean XO activity and 
%CV 






Mean X O R activity and 
%CV 
(pm oles/m inute/ mg 
protein)
69.2
(n-4 ; C V =32%)
7.6
(n -3 ; CV = 15%)
Table 20. Samples of rat heart and liver were assayed for oxidase and total 
activity, using fluorimetric measurement of isoxanthopterin formation.
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3.4 Rabbit aldehyde oxidase purification
Livers (52.5 g and 92.2 g) were obtained from 2  sacrificed rabbits. Crude 
homogenates were prepared as by ultracentrifugation and ammonium sulphate 
precipitation, and aldehyde oxidase was extracted (Materials and Methods 2 .6 .1 ). 
The final stage of the reported protocol (Warne and Stell, 1990) involved anion 
exchange, though in-house attempts to reproduce this stage were unsuccessful, 
and protein could not be eluted from the column.
The pre-anion exchange fraction was analysed by SDS-PAGE and assayed 
for XOR and aldehyde oxidase activity (Table 2 1 ). The bound fractions from the 
p-aminobenzamidine Sepharose 6 B column, and all subsequent fractions had 
negligible XOR activity. From SDS-PAGE, the rabbit aldehyde oxidase appears 
to run slightly more slowly than HXO, with an estimated molecular weight of 
170 kDa compared with 158 kDa (Photograph 20).
The purification was repeated, with the gel filtration and anion exchange 
chromatography stages omitted (Photograph 21), and fractions were tested by 
BXO capture ELISA (Figure 24; Results 3.2.2.3). Crude and pooled peak 
fractions had negligible titre compared with BXO on ELISA.
Attempts by an undergraduate project student to purify bovine aldehyde 




X O R  specific activity 
(nm oles/m inute/m g)
Aldehyde oxidase specific 
activity 
(nm oles/m inute/m g)
Crude rabbit liver homogenate 7.25 1 . 0 37
Unadsorbed (post-benzamidine) 6 . 1 0 6.7 negligible
Benzamidine-adsorbed peak 0.15 4.8 105
Post-gel filtration 0.09 6.9 1450
HX O  (purified in-house) 1.3 4.7 negligible
BXO (commercial) 8 . 1 4600 1 . 8
Table 2 1 . Purified rabbit liver aldehyde oxidase was assayed for XOR and aldehyde oxidase activity. Commercially 
available BXO and freshly prepared H X O  were also assayed.






P h o to g rap h  20. SDS-PAGE gel com paring aldehyde oxidase purified from  rabbit 
liver w ith  H X O  and BXO.
1. Aldehyde oxidase (post gel filtration, pre-anion exchange chrom atography)
2. H X O
3. BXO










P h o to g rap h  21. SDS-PAGE mini-gel com paring aldehyde oxidase from  rabbit 
liver w ith  BXO and H X O .
1. Molecular weight markers
2. BXO
3. H X O
4. Aldehyde oxidase (post-p-aminobenzamidine chrom atography)
5. Molecular weight markers
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BXO
Rabbit aldehyde oxidase peak 












1 0.1 0.01 0.001 0.0001
D ilution from stock
Figure 24. T itration curve for purified rabbit liver aldehyde oxidase, using the p A b /b io tin -p A b  anti-(BXO) capture 
ELISA.
4 Discussion
4.1 Aims of the project
The aims of the project were:
• to produce monoclonal and polyclonal anti-(XOR) antibodies
• to use these antibodies in a non-radioactive, semi-quantitative assay for XOR 
in tissue homogenates
• to investigate the use of anti-(XOR) antibodies in affinity purification of 
XOR from, particularly, human tissues.
4.2 Polyclonal antibody production
Rabbit polyclonal antiserum was produced routinely. Both BXO and H X O  
appeared to be highly immunogenic, and high titres were achieved after the first 
immunization.
The initial strategy for IgG isolation involved ammonium sulphate 
precipitation followed by ion-exchange chromatography. This was replaced by 
purification on a protein A-Sepharose 4B affinity gel, which was more 
convenient and gave a slightly higher yield of IgG (~  100 mg/10 ml antiserum 
compared with 60-80 mg/10 ml; Results 3.1.1.1-2). A fraction of the IgG was 
further affinity-purified on a BXO- or HXO-Sepharose 4B affinity column. An 
IgG fraction and an affinity-purified fraction were prepared from each batch of 
antiserum and, when used together in ELISAs, care was taken to ensure that only 
antibodies from the same batch of antiserum were used.
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The results from ELISA and Western blots of anti-(BXO) pAb against 
BXO and HX O  indicate that avidity with bovine epitopes was greater than that 
with human epitopes, though the antibodies were cross-reactive. Although it is 
not surprising that the antibodies have the greatest avidity for the immunogen, it 
does indicate that some inter-enzyme epitope variation exists. The finding that 
the anti-(HXO) pAb have similar recognition of both the human and bovine 
enzyme forms, however, is unexpected. Either the more immunogenic HXO 
epitopes are conserved in the bovine enzyme or the properties of the affinity- 
purified anti-(HXO) antibodies reflect affinity-purification of selected paratopes.
The instability of HXO cross-linked to CNBr-inactivated Sepharose 4B 
was demonstrated, and made routine affinity-purification of anti-(HXO) 
antibodies impossible. Deterioration of the immobilized enzyme on the affinity 
matrix may have exposed only the more stable of the human epitopes. These 
more stable tertiary characteristics may also be well-conserved between H X O  and 
BXO. Degradation would also, however, be expected to expose novel epitopes 
not exposed on the immobilized BXO molecules and, therefore, recognition of 
the H X O  enzyme by the polyclonal population might be expected to be greater 
than that of BXO. By examining the SDS-PAGE gel of the breakdown products 
of H XO  coupled to Sepharose 4B, it appears that the breakdown does not mirror 
the breakdown patterns of HXO seen on storage (Photographs 2 and 3). If the 
novel epitopes are not exposed in the test HXO sample, then these antibodies 
will not be detected and the avidity of the antiserum will be skewed.
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Furthermore, that an additional elution stage (i.e. at low pH) was required for 
anti-(HXO) pAb using the H X O  affinity column also indicates that the nature of 
some of the anti-(HXO) pA b/H X O  interactions on the affinity column differed 
from those of the anti-(BXO) pAbs on the BXO affinity column.
4.3 Monoclonal antibody production
It was initially hoped to produce monoclonal hybridomas secreting anti-(XOR) 
IgG, as these are readily incorporated into ELISA and affinity chromatography. 
Accordingly, the failure to produce murine hybridoma cell lines secreting IgG 
was disappointing. It became important to use the antibodies available to develop 
techniques within the laboratory that could be optimised with anti-(XOR) IgG 
mAbs, should they become available.
The reason(s) why the established immunization schedule and subsequent 
fusion/clone protocol did not result in mouse IgG-secreting cell lines, is unclear. 
Historically, several other workers in our laboratory had experienced the same 
difficulties and, despite attempts to produce IgG-secreting hybridomas over 
5 years, none had been obtained.
Clearly, in the immunization schedule used for the mice, the class-shift 
was not achieved and the secondary response also produced antibodies from the 
/x-class. It has been suggested, (D. Brennand; personal communication), that the 
IgM antibodies produced in the primary response may had such high affinity for 
the antigen that there was no maturation of class from fi to y.
Another reason for the failure to provoke the classical secondary response 
would be if the secondary immunogen differed from the primary. If this was the
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case, and common epitopes were not recognised, a second primary response would 
be provoked with stimulation of a different antigen-reactive lymphocyte. The 
enzyme preparation used as immunogen for each animal was stored at -20°C 
between immunizations. This was necessary because the enzyme purification 
protocol was being altered and improved constantly, and the purity of the final 
enzyme product was not constant. However, the intact enzyme is a relatively large 
immunogen and would certainly be partially proteolysed preceding antigen 
presentation. That breakdown on storage of the enzyme would differ from this 
partial proteolysis to the extent of a lack of common epitopes seems highly 
unlikely. In addition, the same problem occurred with BXO as immunogen. This 
is more stable than the human enzyme and is commercially available as a 
consistently pure form.
The final inconsistency was the ability of the same immunogen to provoke 
an IgG response in the rabbit, though the immune mechanism may be complicated 
by the existence of ‘natural’ anti-(XOR) antibodies. High concentrations of anti- 
(XOR) IgG have been reported in the sera of, among other animals, both the New 
Zealand white rabbit and the BALB/c mouse, (Bruder et al., 1984). The positive 
titre of the normal (i.e. non-immunized) rabbit serum (Figure 9, Results 3.1.1) does 
indeed indicate circulating anti-(XOR) Ig is present in the laboratory rabbits used 
for pAb production, prior to immunization. In contrast, the normal mouse serum 
had negligible anti-(XOR) titre (Figure 13, Results 3.1.2), in disagreement with the 
findings of Bruder et al. (1984).
The proposed hypothesis to explain the presence of ‘natural’ anti-(XOR) is 
that XOR is released following cell damage and induces an immune response,
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though the lack of immunological tolerance is not explained. Most ‘natural’ 
autoantibodies belong to the IgM class (Avrameas, 1983) and are low affinity and 
thymus-independent (reviewed in Roitt, 1994). If the rabbits used for pAb 
production were already producing anti-(XOR) before immunization, then the 
introduction of XOR at immunization would stimulate a secondary response. 
This may explain the relatively high titres after the first immunization. In mice, 
however, the first immunization provokes the primary response and XOR 
appears to act as a thymus-independent antigen, such that the response is mainly 
IgM and memory cells are not generated. However, this phenomenon does not 
appear to be common to all BALB/c mice, as several groups have reported the 
generation of hybridomas generating anti-(XOR) monoclonal IgG (Bruder et al., 
1983; Hellsten-Westing, 1993). The reported generation of mAbs in the same 
laboratory as that reporting naturally occurring anti-(XOR) antibodies (i.e.
Bruder et al., 1984) should be appreciated. If the mice used for hybridoma 
preparation already had circulating anti-(XOR) Ig, then a situation analogous to 
that described for rabbits might have occurred (i.e. response to immunization was 
secondary).
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With hindsight, the inability of mice used in our laboratory to respond to 
X O R stimulation may have been signalled by the negligible anti-(XOR) titres of 
the normal mouse serum. In future, using another strain of mouse (e.g. C57B1 or 
CBA) or another species (e.g. rat) for anti-(XOR) hybridoma production might 
prove more successful. It would be of interest to investigate whether the 
existence of pre-existing anti-(XOR) antibodies impacts on the ability to generate 
IgG-secreting clones, and why XOR immunization in the mice used in our 
laboratory was not able to stimulate a secondary, IgG response.
Another strategy for the production of an IgG-secreting hybridoma line 
would be to isolate cells, if any existed, in which class switching had occurred. 
This technique requires a fluorescence-activated cell sorter (FACS) and a trained 
operator. Selection of small numbers of IgG-secreting cells followed by clonal 
expansion of the selected cells and a repetition of the exercise would be time- 
consuming and expensive, but represents an alternative approach to that used to 
date.
4.4 Anti-(XOR) monoclonal IgM
The anti-(XOR) hybridoma cell lines H3G7 and B5B4 appeared to recognise 
epitopes common to the bovine and human enzyme. Similarly, 2A3 and 2G3 
gave positive staining on Western blots of both human and bovine enzyme.
That one of the established hybridoma cell lines, H 2 C 2 , was secreting IgG 
antibody against a contaminant illustrates the problem of enzyme purity for the 
purpose of antibody generation. This antibody did not stain nitrocellulose in a 
Western blot, and it was only when the antibody was coupled to Sepharose 4B
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and used for affinity purification that the nature of the antigen was established. 
By comparing titres against different preparations of enzyme, the nature of the 
problem was confirmed (Figure 14, Results 3.1.3).
The IgM antibodies were of little use in ELISA. The absence of coloured 
end-product in the assay when one mAb population coated the plate and the 
alternative biotin-mAb population was used as the secondary detector antibody, 
would also suggest the two lines H3G7 and B5B4 recognised a common epitope. 
This was also indicated by subsequent surface plasmon resonance measurements 
(Appendix III).
Although the use of monoclonal IgM in ELISA was not pursued it is 
worth, for future reference, highlighting a potential problem associated with 
using hybridoma supernatant in a biotin-dependent assay. Biotin is present in the 
tissue culture media and, if not removed during antibody purification steps, will 
interfere with the assay. As high non-specific coloration did not routinely occur 
in the ELIS As using mAb, it appears that the biotin was either removed during 
antibody purification or was not immobilized on the plate. If future assays 
incorporate hybridoma supernatant, the effect of non-specific biotin on the 
results should be appreciated.
4.5 Development of ELISA to measure HXO and BXO
Inhibition ELISAs using the mAbs did not give useful reference curves, and 
optimization was not pursued. Capture ELISAs using biotin-labelled polyclonal 
IgG was, however, more successful.
The initial success of the ELISA could not be repeated using later batches
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of antibodies, leading to speculation on differences between batches. From the 
results of later assays, it appears that the success of the first capture ELISAs was 
due to the non-affinity purified IgG fraction being free from enzyme. The failure 
to reproduce the preliminary results was confusing and much time was spent 
purifying further batches of IgG in order to replicate the initial standard curves.
It was only when the majority of batches gave the pattern of high background 
coloration in the absence of antigen, consistent with the presence of immune 
complexes, that the magnitude of the problem was appreciated.
The presence of immune complexes of IgG and XOR in the antisera 
could, again, be explained by high concentrations of circulating anti-(XOR) Ig in 
normal rabbits (Discussion 4.2). The presence and distribution of immune 
complexes in blood reflects the amounts and relative proportions of antibody and 
antigen. It may be that later boosts of XOR resulted in antibody and antigen 
excess, with the consequential formation of circulating complexes.
It appears that the antibodies used in the first ELISAs were prepared from 
antiserum not containing immune complexes. It may have been collected after 
the first immunization, or it may be that the immunization schedule did not 
cause antibody and antigen excess in that rabbit. Later batches of antiserum, 
however, do appear to have contained immune complexes formed as a result of 
overstimulation.
Future immunization protocols should use minimum amounts of 
immunogen and continued boost/bleed regimens may not be possible. Immune 
complexes should be removed by precipitation or gel filtration.
Returning to the results achieved with the working capture ELISA, it was
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initially surprising that substitution of H XO in the ELISA for BXO gave 
negligible end-point coloration. Given, however, that the anti-(BXO) pAb titre 
against H X O  was an order of magnitude lower than that against BXO (Table 7, 
Results 3.1.1), in view of the sensitivity of the assay, this result seems to have 
reflected the lower anti-(HXO) affinity of the anti-(BXO) antibodies.
The use of biotin-labelled antibody in the capture ELISA, with subsequent 
detection by streptavidin- (or Extravidin-) labelled HRP, avoids the use of a 
tertiary anti-(Ig) antibody and thus avoids a possible source of background cross­
reactivity. Biotinylation of antibody is straightforward; it is easy to manipulate 
the reaction to increase or decrease the amount of biotin label, as required. Since 
avidin has four biotin binding sites, it would be possible to amplify the assay by 
pre-incubating the streptavidin or Extravidin with biotin before incubation with 
the assay mixture. This was not investigated in this project but may merit future 
consideration.
In order to further improve the capture ELISA, particularly with regard 
to specificity, it will be necessary to generate two mAb populations, each 
recognising different epitopes. Even one anti-(XOR) monoclonal IgG, used with a 
polyclonal preparation, will be more powerful than the pAb/pAb ELISA. 
However, when one or more hybridomas secreting high-affinity monoclonal IgG 
becomes available, it should be possible to substitute mAbs for pAbs.
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4.6 Partial purification of BXO
Preliminary experiments were designed using affinity-purified rabbit anti-(BXO) 
pAb cross-linked to protein A/Sepharose 4B.
Enzyme activity was totally removed from a crude bovine milk fraction 
by recycling through the anti-(BXO) affinity column (Results 3.3.2). This was an 
encouraging result as it demonstrated that the elution conditions (i.e. 0.05 M 
diethylamine, pH  11.5, containing 0.5 M sodium chloride) did not affect enzyme 
activity. However, it should be noted that the bovine milk sample had lower 
activity than that reported by Abadeh et al. (1992), 11.2 m U /m l compared with 
73 m U/m l. The reason for this is unclear but the purpose of the experiment was 
simply to establish whether enzyme could be removed from a heterogeneous 
medium and whether the enzyme retained activity following elution from the 
affinity column. The lower capacity of the column for H XO (i.e. ~  15%) is likely 
to be another consequence of the lower HX O affinity of anti-(BXO) antibodies.
This experiment was followed by recycling a crude bovine liver 
homogenate through the affinity column. Again, the purpose of this experiment 
was to test whether the affinity matrix could remove active enzyme from a crude 
tissue homogenate. Probing with the anti-(BXO) mAb B5B4 confirmed the 
presence of BXO in the eluted peak.
A concern with this method of affinity purification was that the relatively 
harsh elution conditions might strip the antibody from the column. Hence, it 
was important to establish that the eluted bands running with Mw around 25 and 
50 kDa did not represent IgG heavy and light chains. Evidence supporting this 
was provided by the Western blot. If rabbit IgG was present in the adsorbed
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fraction, when the nitrocellulose was incubated with the secondary antibody, the 
goat anti-(rabbit) antibody would have detected the corresponding heavy and 
light chains, and these bands would have stained heavily. This did not occur, 
indicating that rabbit antibodies were not present in the adsorbed fraction.
4.7 ‘HXO-like’ protein in three human tissues
Protein recognised by anti-(XOR) mAbs and pAb was detected in human heart, 
smooth muscle and liver homogenates (Photographs 11 and 12; Results 3.3.5). 
From  SDS-PAGE, it appears that antigenic bands running in the region of the 
intact H XO monomer occur only in heart, though even here the bands appear to 
correspond to slightly higher molecular weights (150 and 143 kDa compared with 
141 and 136 kDa). Interestingly, the non-specific Ponceau S staining of 
nitrocellulose before probing with antibodies indicates faint bands running in the 
same position as the 141-kDa HX O  band. These were not, however, recognized 
by either mAb or the pAb.
Similar patterns of detection occurred with smooth muscle and liver, 
though staining of bands corresponding to Mw < 60 kDa was weak with smooth 
muscle. The heart pattern differed from the smooth muscle/liver pattern above 
around 60 kDa, but was similar at lower Mw. If these bands represent H XO, this 
suggests differences exist between the cardiac and non-cardiac enzymes.
The recognition of major bands in the smooth muscle and liver lanes, 
corresponding to Mw~90 and 70 kDa, by anti-(BXO) pAb and anti-(HXO) mAb, 
but not by anti-(BXO) mAb suggests that the epitope for B5B4 is not accessible
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on these bands. That these bands do not occur in the heart lane further supports 
the hypothesis that the cardiac and non-cardiac forms differ. Obviously, cross­
reactivity of the antibodies may mean that some or none of the bands 
correspond to HXO. Multi-antibody detection does, however, strengthen the 
evidence that certain bands indicate HXO protein.
4.8 Partial purification of ‘HXO-like’ protein from 
human tissue
The major limitation of this set of experiments was the use of an anti-(BXO) 
pAb affinity column to purify human enzyme. As discussed previously, the anti- 
(BXO) pAbs appeared to have lower affinity for the HXO. However, in the 
absence of enough affinity purified anti-(HXO) antibodies to construct a similar 
anti-(HXO) column, preliminary purifications were attempted with the anti- 
(BXO) column.
Results from an experiment using the column to remove H X O  from a 
crude human liver preparation are confusing. A very small fraction of enzyme 
activity was removed but the unadsorbed fraction, despite having protein content 
approximately half that of the initial crude fraction, had almost double the 
activity of the crude. This implies that the activity of the unadsorbed fraction has 
been increased by the removal of protein. A high-molecular-weight, competitive 
inhibitor of XOR has been reported to copurify with XOR from bovine milk 
(Bray, 1959). Although non-dialysable, it is claimed that the effects of the 
inhibitor on enzyme activity may be overcome by precipitation with 60%
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ammonium sulphate (Lee, 1973), or by high substrate concentration (~500 /xM 
xanthine; Bray, 1959). In addition, Terada (1994) demonstrated the presence of a 
high-molecular-weight inhibitor in rabbit heart homogenate. If a similar inhibitor 
was present in the human liver preparation, and was adsorbed by the anti-(BXO) 
affinity column, the unadsorbed fraction would be expected to have reduced 
protein content and increased activity. Although this is an attractive theory, it 
means that anti-HXO inhibitor antibodies were generated by BXO immunization 
and purified with anti-(BXO) antibodies on affinity purification. As the 
commercially prepared BXO used to immunize rabbits showed no trace of high- 
molecular-weight contaminants on SDS-PAGE, and had high XOR activity, it is 
highly unlikely that the rabbit generated specific anti-inhibitor antibodies 
following immunization with BXO. Alternatively, in vivo association of native 
inhibitor with immunogen, might provoke an immune response.
If the presence of inhibitor somehow facilitated HXO recognition by the 
anti-(BXO) pAb, then enzyme associated with inhibitor would be expected to 
bind preferentially. O n diethylamine elution, the enzyme/inhibitor complex 
would elute from the column. If the inhibitor had a molecular weight in the 
order of that indicated for the rabbit myocardial XOR inhibitor (i.e. 
approximately 370 kDa) it would not appear on SDS-PAGE gels, though 
fragments might be visualized. Furthermore, the presence of an inhibitor in the 
adsorbed fraction might explain the low XOR activity of this fraction, which is 
at odds with the amount of H XO protein seen on the SDS-PAGE gel. 
Preliminary evidence suggests that inhibitory activity might be associated with a 
60-kDa fragment visualized on SDS-PAGE (see later discussion).
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Another explanation of the increased H X O  activity of the unadsorbed 
liver fraction could be the failure to totally remove BXO from the column 
following the bovine tissue experiments. The residual enzyme could be non- 
specifically washed out with the unadsorbed human homogenate. However, this 
seems unlikely as the column was thoroughly cleaned following the bovine 
experiments and baseline resolution was achieved with washes prior to the 
application of human homogenate. However, the possibility of bovine enzyme 
contamination cannot be disregarded. When the experiment was repeated later, 
after several other partial purifications, the protein concentration of the adsorbed 
peak in terms of initial tissue mass had decreased from 0.17 mg/g wet weight 
human liver to 0.0025 mg/g wet weight. This also suggests contamination in the 
first adsorbed peak, but could equally be explained by a decrease in efficiency of 
the column due to non-specific protein binding to the column.
As suggested by previous SDS-PAGE and subsequent Ponceau S staining 
of the blotted nitrocellulose (Photograph 10, Results 3.3.5), bands running in the 
same position as H X O  were visualized in the crude liver homogenate (Results 
3.3.6, Photograph 13). In contrast to the detection pattern achieved using anti- 
(BXO) pAb on crude homogenate, protein corresponding to these bands on SDS- 
PAGE was present in the anti-(BXO) pAb adsorbed fraction. The failure to 
detect the double band on Western blot may reflect low avidity for the ‘HXO- 
like’ band. Alternatively, the ‘HXO-like’ protein adsorbed by the affinity column 
may have been strongly associated with another protein (e.g. corresponding to 
bands — 64 and 27 kDa) for which the pAb has strong avidity. It may, therefore, 
have been non-specifically bound to the affinity column via strong association
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with a specifically bound protein. It is tempting to suggest that these bands 
represent fragments of the inhibitor protein discussed earlier. The major band at 
around 64 kDa was recognised only by the pAb (Photograph 12, Results 3.3.5). If a 
subset of the anti-(XOR) pAb had been raised against this protein, had not been 
removed by anti-(BXO) affinity chromatography, and had, together with anti- 
(BXO) pAb, been cross-linked to Sepharose 4B, inhibitor may be present in the 
adsorbed fraction.
A similar band, running at around 64 kDa, was adsorbed from the bovine 
liver homogenate (Photograph 9, Results 3.3.9). In contrast to the human liver 
blot, probing of the bovine liver blot with anti-(BXO) pAb resulted in very faint 
staining of this band (Photograph 9, Results 3.3.9). Extending the hypothesis that 
this band corresponds to the presence of an inhibitory protein, that it is present in 
liver and smooth muscle extracts, but not heart, implies that this protein-mediated 
inhibition does not occur in heart. Although a preliminary finding, the indication 
that the affinity-chromatography unadsorbed liver fraction had higher specific 
XOR activity than the crude homogenate and that this was not the case for heart 
homogenate, also supports this theory.
In order to gain insight into another of the original project aims (i.e. to 
demonstrate the existence of the enzyme protein in human heart tissue) the 
experiment was repeated with human heart homogenate.
The experiment was repeated twice, under the same conditions, and the 
enzyme activities of the adsorbed fractions, measured using the fluorimetric pterin 
assay, were not significantly different (i.e. within 2  standard deviations).
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In contrast to the situation with liver, the unadsorbed fraction had negligible 
XOR activity.
The values obtained for the XOR activity from extracts of human heart 
are considerably lower than the positive values reported, i.e. 0.27-1.61 /zU/g wet 
weight of tissue compared with 0.3-37 m U /g wet weight of tissue (Muxfeldt and 
Schaper, 1987; Wajner and Harkness, 1989; de Jong et al., 1990; Table 5, 
Introduction 1.2.4). It should be noted, however, that when enzyme activity has 
been recorded in human heart tissue previously, the tissue had been stored at 
0-4°C and was, by implication, relatively fresh (Table 2 2 ). When tissue has been 
deep frozen, no activity has been detected. It is possible, therefore, that freezing 
decreases the activity to such a low level (i.e. in the range of pmoles/min/g 
tissue) that previous groups have not been able to detect it. However, Eddy et al. 
(1987) used a fluorimetric assay and conditions similar to those used in our 
laboratory, and did not detect enzyme in tissue that had been deep frozen. This 
group concluded that activity must have been below 2 . 0  nU/g. 
Immunohistochemical studies do not appear to be affected by storage, as XOR 
epitopes were detected in tissue stored at 0-4°C and -70°C. Thus deep-frozen 
tissue appears to maintain native epitope conformation sufficient for antibody 
recognition.
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The choice of postmortem vs biopsy tissue sample may also affect assay results. 
Loss of up to 38% enzyme activity has been reported in postmortem rat liver for 
3 hours at 22°C and then 2  hours at 4°C (Kooij et al., 1992b). It appears, 
therefore, that XOR activity is affected by length and temperature of storage.
A uthor X O R activity Storage tem perature
de Jong et al., 1990 + 0-4°C
Eddy et al., 1987 - -70°C
Grum et al., 1989 - -80°C
Kooij et al., 1992 - -80°C
Muxfeldt and Schaper, 
1987
+ 0-4°C
Podzuweit et al.t 1991 - -196°C
Wajner and Harkness, 
1989
+ 0-4°C
Table 2 2 . The relationship between tissue storage temperature and reported XOR 
activity in human heart.
In both samples of heart protein eluted from the anti-(BXO) affinity 
column, XDH activity accounted for approximately 20% of total XOR activity. 
This differs from results reported by Wajner and Harkness (1987), and Muxfeldt 
and Schaper (1989). Both groups demonstrated that XDH contributed around 
95% of XOR activity. Though care was taken to ensure that protease inhibitors 
and DTT were added at all stages of tissue homogenization, they may have been
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removed from the bound fraction during affinity chromatography, allowing 
conversion to occur. Alternatively, the ratio of XDH:XO may reflect the 
enzyme state within the postmortem samples.
That the ratio is similar to that found in the rat tissues assayed, however, 
indicates that the homogenization conditions do not prevent all XDH to XO 
conversion, and approximately 80% of the enzyme converts to the oxidase form.
Reference to the results of XO and XOR activity fluorimetric assays of 
rat heart and liver indicates that the in-house fluorimetric assay may have been 
giving low values. Although the assay was calibrated with a fresh isoxanthopterin 
standard on each occasion, activities determined for rat heart and liver were 
lower than those reported. For example, Battelli et al. (1972) report that rat liver 
homogenate has XOR activity of 340 m U /g tissue, whereas our in-house assay 
gave a value of 4.6 mU/g. Similarly, reported values for XOR activity in rat 
heart range from 9 to 77 m U /g wet weight tissue (Table 1 , Introduction 1 .2 .1 ) 
whereas the in-house assay measured 0.28 mU/g. As all in-house measurements 
were made using the same assay conditions and equipment, comparison between 
data sets can be made with confidence.
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In practice, many factors are likely to affect XOR activity, including:
•  gender and diet of laboratory animal
•  tissue state (i.e. fresh vs frozen)
•  method of extract preparation
•  assay
•  storage conditions (discussed previously)
•  pathophysiological state of the tissue.
Though Eddy et al. (1987) used a fluorimetric assay similar to the in-house assay, 
homogenization conditions differed and, perhaps more significantly, they obtained 
heart from an unconscious rat, whereas the measurements reported here were made 
using heart removed shortly after death.
It may also be significant that, when a relatively high XOR activity has 
been reported for human heart, the assay has included a relatively high substrate 
concentration, 69-345 mM xanthine (Muxfeldt and Schaper, 1987) and 750 mM 
xanthine (Wajner and Harkness, 1989). The apparent Km of the enzyme for 
xanthine is about 18 mM (Abadeh et al., 1992) and other groups employing 
biochemical assays of human heart XOR activity have used xanthine 
concentrations in the range 50-95 mM (Eddy etal., 1987; Podzuweit et al., 1991). 
The presence of a high molecular weight XOR inhibitor, the effects of which can, 
reportedly, be overcome at high substrate concentrations has been described 
previously. The in-house spectrophotometric assay used 100 mM xanthine, which 
may have been too low to overcome the effect of similar inhibitors present in the 
homogenate. A further complicating factor is that tissue homogenates contain a
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range of potential biochemical inhibitors of XOR activity, including uric acid, 
xanthine and N A D H  (Kaminski and Jezewska, 1979).
The pathophysiological state of the tissue may also affect the XOR activity, 
as enzyme leakage from diseased tissue is a well-known phenomenon. For example, 
XOR leakage from diseased liver has been reported (Shamma'a, 1965) leading to 
speculation that the reported XOR activity of human tissues removed from 
subjects with diseased liver, may be falsely high (Kooij et al., 1992b). The presence 
of serum XOR should be borne in mind when assessing all reports of tissue levels. 
All work on human tissue has, to date, used samples obtained during surgery or 
postmortems, with no reference to the state of general health or, in particular, 
hepatic function. There is, therefore, no way of retrospectively relating XOR 
activity to evidence of hepatic disease. The use of immunohistochemical and 
molecular techniques will help overcome this problem, by localizing the enzyme 
directly. However, the source of XOR activity in tissue homogenates should be 
investigated fully (e.g. serum XOR measurements should be made in parallel).
Affinity-purification using the anti-(BXO)/protein A column was repeated 
several times in order to run the fractions on SDS-PAGE and Western blot.
From the Western blot, it appears that the enzyme is present in human smooth 
muscle, heart, and liver. Detailed characterization of the enzyme from each source 
was not performed as the purification were extremely crude.
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The adsorbed fraction can be termed ‘HXO-like’ as it was recognised by 
cross reactive anti-(BXO) Ig and eluted under conditions of high pH. This may, 
however, reflect the nature of the immobilized pAb, rather than in vivo HXO.
4.9 Aldehyde oxidase from rabbit tissue
Aldehyde oxidase is closely related to XOR and is reported to have an equally 
wide distribution (Krenitsky et al., 1974). It is always a matter of concern, 
therefore, that the enzyme under investigation is neither wholly aldehyde 
oxidase, nor a preparation contaminated with that enzyme.
Purification of aldehyde oxidase from rabbit liver, using the method 
described (Methods 2.6.1), proved relatively simple. Although direct comparison 
of rabbit aldehyde oxidase with BXO or HXO was limited by consideration of 
interspecific variation, it was important to assess the specificity of the 
spectrophotometric and fluorimetric assays of enzyme activity. Rabbit aldehyde 
oxidase, when substituted for XOR in both the fluorimetric and 
spectrophotometric assay, had negligible activity. Similarly, BXO and H XO had 
negligible activity when substituted for aldehyde oxidase in the 
spectrophotometric assay for aldehyde oxidase activity. While this result was 
reassuring, an ideal comparison would have used aldehyde oxidase isolated from 
bovine and human tissue. Similarly, that anti-(BXO) pAb did not appear to cross- 
react with rabbit aldehyde oxidase on ELISA is not, in itself, an indication the 
antibodies raised do not cross-react with bovine aldehyde oxidase. One cause for 
concern is, however, that rabbit aldehyde oxidase runs slightly more slowly than 
HXO on SDS-PAGE (Photograph 20; Results 3.4), and as does the ‘HXO-like’
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protein extracted from human heart (Photographs 1 1  and 1 2 ; Results 3 .3 .5 ). 
Future experiments should address this issue, and a suggested approach is 
discussed later (Discussion 4.9.3).
The failure to obtain bovine aldehyde oxidase from liver using the same 
protocol as that used for rabbit enzyme may reflect the difference in reported 
aldehyde oxidase activities (i.e. rabbit aldehyde oxidase reduces 1980 nmoles 
ferricyanide/minute, contrasting with 1 0 0  nmoles ferricyanide/minute reported 
for Hereford cow; Krenitsky et al., 1974). While the XOR plus aldehyde oxidase 
content of liver appears to be constant between the two species (i.e. 
approximately 160 mg protein/g tissue), the ratio of XORraldehyde oxidase, in 
terms of ferricyanide reduction, is 3:1 for bovine liver, and 1:12 for rabbit liver.
Future attempts to purify aldehyde oxidase from a bovine source, 
therefore, should start with a far greater initial tissue mass (probably around 
600 g). Although this would make initial stages more cumbersome, by increasing 
the number of ammonium sulphate precipitation stages, the crude homogenate 
could be quickly reduced to a more manageable volume. There is no reason why 
the method used to purify the enzyme from rabbit liver could not be used for 
purification of aldehyde oxidase from bovine or, indeed, human liver.
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4.10 Recommendations for future work
4.10.1 Generation of polyclonal, anti-(XOR) antibodies
The presence of circulating anti-(XOR) antibodies prior to immunization, should 
be determined and the effect on post-immunization titres assessed. Immunization 
protocols should use the lowest amount of immunogen that still provokes a good 
response. Although this will have to be determined empirically, it may be 
possible to immunize effectively with less than 100 ^g BXO or HXO.
When the rabbit has a relatively high pre-immunization anti-(XOR) titre, 
it may be prudent to sacrifice the animal 10 days after the first immunization. In 
any case, antiserum collected from each bleed should be tested for immune 
complexes, and batches of antiserum should not be pooled. If immune complexes 
are present, care should be taken to remove the contaminating enzyme during 
IgG preparation, either by precipitation or gel filtration.
4.10.2 Production of monoclonal anti-(XOR) IgG
Investigation of the effect of pre-immunization anti-(XOR) titres on successful, 
IgG-secreting hybridoma production should be pursued. Tail bleeds from a 
population of BALB/c mice should be screened for anti-(XOR) antibody. Anti- 
(XOR)-positive mice should be immunized and splenocytes used for hybridoma 
production, in tandem with splenocytes from immunized anti-(XOR)-negative 
mice.
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As discussed previously, fusions using splenocytes from other strains of 
mouse or, more radically, other species of laboratory animal, may present 
alternatives to the currently unsuccessful in-house method of anti-(XOR) IgG 
production.
If mice with pre-immunization anti-(XOR) titres are not found, and other 
strains or species are not available, immunizations schedules should be performed 
over the maximum length of time allowed under Home Office Regulations, using 
the minimum amount of XOR (~  1 0  f i g ) .
As demonstrated by the monoclonal H2C2, it is important to establish 
the source of the mAb’s epitope before starting any immunological 
investigations. Western blots should normally allow visualization of the target 
protein but, in some cases, the conformational change induced by the SDS-PAGE 
and subsequent Western blotting procedure may disrupt the epitope. Although 
coupling of the antibody to CNBr-inactivated Sepharose 4B is a relatively time- 
consuming procedure, it provides reliable indication of the antigen. If the nature
i
of the antigen is suspected (e.g. the 80 kDa contaminant), and a homogeneous 
preparation of the suspected protein is available, mAb/suspected antigen 
interaction can be estimated by ELISA or, more rapidly, using plasmon surface 
resonance measurements (Appendix III).
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Once IgG-secreting hybridoma lines have been established, it will be 
necessary to determine the molecular weights of the light and heavy chains (from 
SDS-PAGE gels). It would also be useful to record weight per unit volume (this 
measurement is more useful than titre in routine mAb work), and the affinity of 
each antibody population (derived from Scatchard plot analysis).
4.10.3 Replacing pAb with mAb
As monoclonal anti-(XOR) IgG was not available during this project, various 
experiments have been described using polyclonal IgG, with the knowledge that 
such heterogeneous systems are not ideal. When one or more hybridomas 
secreting high-affinity anti-(XOR) monoclonal IgG becomes established, the 
monoclonal IgG can be substituted for polyclonal IgG in the methods described, 
increasing specificity and reproducibility.
Again, once hybridoma supernatant is routinely available, a standard 
purification strategy can be established. In order to obtain mAb preparations of 
high purity, it will be necessary to determine:
• Pi
• pH  stability
• ionic stability at high and low ionic strengths
• hydrophobicity.
For preparations above 50% purity, a standard protocol will incorporate 
clarification stages, protein A affinity purification, ion exchange chromatography 
(the type depends on the pi), followed by gel filtration.
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Purified anti-(XOR) mAb can be substituted directly for pAb on affinity 
columns. The protocol for cross-linking antibody to protein A will be similar. 
Similarly, anti-(XOR) mAb/protein A/Sepharose 4B-beads prepared in the same 
way could be added directly to small volumes of tissue extract, and used to 
extract antigen.
High-affinity IgG will also be a powerful immunohistochemical tool. 
Although Hellsten-Westing (1993) has reported immunohistochemical 
investigation with an anti-(XOR) mAb in human tissues, such antibodies will be 
of great value in cell culture work and, in particular, investigation of molecular 
activation-deactivation mechanisms.
The nature of high-affinity anti-(XOR) IgG association with aldehyde 
oxidase will be of considerable interest. The preparation of purified bovine and 
human aldehyde oxidase (suggested modifications to the protocol for rabbit 
aldehyde oxidase have been made previously; Discussion 4.8) will allow more 
detailed comparisons and cross-reactivity studies to be pursued. Specific anti- 
aldehyde oxidase) mAb would complement anti-(XOR) studies. It is interesting 
that all immunological investigations of XOR in mammalian tissues have ignored 
the effects of cross-reactive aldehyde oxidase.
( One of the most important questions raised by this project
concerns the preliminary indication that an inhibitor protein may be present in 
vivo, in non-cardiac tissues. Further investigation with a range of anti-(XOR) 
mAbs will determine whether this is, in fact, an XOR fragment.
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Isolation and characterization of the protein corresponding to the 64-kDa protein 
will be necessary to study its interactions with XOR in detail.
With increasing knowledge of the primary, secondary and tertiary 
structure of XOR (see, for example, Appendix IV) and increasingly powerful 
molecular engineering techniques, it should be possible to make specific antigens 
comprising specific parts of the XOR enzyme. For example, by large-scale 
production of enzyme fragments in their proposed altered conformational states, 
it may be possible to generate highly specific mAbs specific for different 
conformational states. These would then allow thorough investigation of the 
nature of the enzyme, under physiological and pathophysiological conditions. In 
addition, specific anti-(BXO) and anti-(HXO) mAbs will allow investigation of 
the origin of naturally occurring anti-(XOR) antibodies.
Xanthine oxidoreductase is a complex enzyme that can exist in different 
states in vitro. Because of its potential to generate free radicals, its distribution 
and activity has been studied extensively, but reported results have often been 
disparate.
Biochemical studies of the enzyme cannot encompass the effects of 
different enzyme forms. These studies should, therefore, be complemented with 
immunological investigations of XOR protein. The ideal system will incorporate 
a range of highly specific anti-(XOR) monoclonal antibodies, class IgG. Although 
the production of these antibodies was unsuccessful during this project, the 
experience gained will be of great assistance to the next investigator. Similarly, 
the in-house methodology established for the use of IgG in the study of XOR 
will be easily modified to incorporate anti-(XOR) mAbs.
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Preliminary experiments with anti-(XOR) pAb indicate that an ‘HXO- 
like’ protein is present in liver, heart and smooth muscle. The low specific 
activity of the heart enzyme is in agreement with reports indicating that most of 
the heart enzyme is in a form largely inactive in conventional assays of XOR 
activity. This is the first report of XOR activity in human heart that has been 
deep frozen. Very early results also suggest the existence of an XOR inhibitor in 
liver but not in heart.
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Improving the in-house purification of HXO from human milk was an ongoing 
project in our laboratory. As HXO at various stages of the preparation is 
referred to in the text, an outline of the standard protocols used is presented.
Preparation of crude extract from human milk
To a sample of fresh (i.e. expressed within 8  hours) human milk, were added:
EDTA 1 mM
DTT 2.5 mM
Sodium salicylate 1.25 mM
Leupeptin 1 /xg/ ml
Antipain 1 /xg/ ml
Aprotinin 1 /xg/ ml
Pepstatin A 1 /xg/ml.
The milk was stirred, then centrifuged at 3000 g, 6 °C, for 30 minutes. The cream 
was collected using a spatula, and resuspended in an equal volume 0.2 M 
dipotassium hydrogen phosphate buffer, containing 1  mM EDTA, 1.25 mM 
sodium salicylate and 2.5 mM DTT. The mixture was stirred for 1  hour at 4°C, 
and then centrifuged at 3000 g, 6 °C, for 30 minutes. The aqueous supernatant 
was collected and cold (4°C) 15% (v/v) butan-l-ol was added, with constant 
stirring. Ammonium sulphate, 15% (w/v), was added with constant stirring, and 
the stirring was continued for 1  hour. The mixture was centrifuged at 13,000 g, 
4°C, for 20 minutes. Ammonium sulphate, 20% (w/v) was added to the 
supernatant and, again, the mixture was stirred for 1  hour. The mixture was
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centrifuged at 10,000 g, 4°C, for 30 minutes; the precipitate was resuspended in 
an appropriate buffer (depending on the next stage). The resuspended pellet was 
dialysed against the same buffer overnight.
Calcium phosphate chromatography
The crude H X O  preparation was resuspended in, and dialysed against, 200 mM 
disodium hydrogen phosphate buffer, pH  6.0, containing 1 mM EDTA, 1.25 mM 
sodium salicylate and 2.5 mM DTT. A calcium phosphate chromatography 
column was equilibrated with the same buffer. The crude H XO preparation was 
slowly applied to the column. Unadsorbed protein was washed from the gel with 
the starting buffer. Bound HXO  was eluted using the same buffer containing 5% 
(w/v) ammonium sulphate.
Although this method did, on occasions, yield pure H XO (as judged by 
SDS-PAGE and A450 :A28o ratio close to 5) it was not reproducible and the 
calcium phosphate chromatography columns were very short-lived. Also, the 
80 kDa contaminant seemed to co-elute with H XO using this method, and an 
alternative was sought.
Heparin chromatography
This provided a good alternative to calcium phosphate chromatography. The 
results were reproducible and the resulting H XO preparation was routinely of a 
higher purity.
The crude H XO preparation was resuspended in, and dialysed against, 25 
mM sodium phosphate buffer, pH  7.5, containing 1 mM EDTA, 1.25 mM
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sodium salicylate and 2.5 mM DTT. It was slowly recycled through a 1 0  ml 
heparin-agarose chromatography column, that had been equilibrated with 
25 mM sodium phosphate buffer, pH  7.5, containing 1  mM EDTA, 1.25 mM 
sodium salicylate and 2.5 mM DTT. Bound protein was eluted with the same 
buffer containing a range of sodium chloride concentrations, 0.1-1 M. Bound 
H X O  eluted with buffer containing 0.4 M sodium chloride.
Further purification
Further attempts to purify the post-heparin H XO used gel filtration, 
hydrophobic interaction, or folate affinity chromatography. None of these, 
however, became routine during the course of the project.
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Appendix III
BIAcore surface plasmon resonance measurement of HXO/mAb interaction
Samples of monoclonal antibodies H2C2 (anti-XO IgG on sensorgrams), B5B4 
(B5 on sensorgrams), and H3G7 (H3 on sensorgrams) were sent to The London 
Hospital for analysis.
The BIAcore surface plasmon resonance sensor measures antibody/antigen 
association in real time. Measurements can, therefore, be used as an indicator of 
antibody affinity.
As the H X O  used was from a calcium phosphate preparation (Appendix 
II), it was likely that it contained the 80 kDa contaminate. If this was the 
case, then Figure 25 can be interpreted as follows. H2C2 binds the 80 kDa 
contaminant in the HX O  preparation. Subsequent addition of H3G7 and then 
B5B4, however, causes no increase in RU, as neither antibody recognises the 
immobilized protein. Similarly, Figure 26 clearly demonstrates a lack of 
recognition by H2C2 for BXO. When H3G7 or B5B4 were used as the primary 
antibody, however, H2C2 was still able to interact with an immobilized antigen 
(Figures 27 and 28, respectively).
Taken together, these results imply that the 80 kDa and H X O  proteins 
are associated in the H XO preparation. O n binding H2C2, the epitope(s) for 
both H3G7 and B5B4 are obstructed and, hence, the relatively bulky IgM 
antibodies are not able to bind. If the HXO binds to the IgM antibodies first, 
however, the IgG antibody is till able to interact with its antigen. Figures 27 and 
28 also indicate that H3G7 and B5B4 have relatively low affinity for HXO.
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anti-XOIgG/HXO/H3/B5
1 8 0 0 0  -
1 7 5 0 0  -
1 7 0 0 0  -
R 1 6 5 0 0  -
1 6 0 0 0  -
1 5 5 0 0  -
1 5 0 0 0
0 500 1500 2 0 0 01 0 0 0 2 5 0 0
Time [ s ]
APR0G FC Time Window AbsResp SD Slope LRSO Baseline RelResp Id
XO 2 57.50 5.00 16434 0.59042 -0.18237 0.53874 YES 0 baseline
XO 2 567.40 5.00 17454 1.74004 -0.05346 1.94221 NO 1020 anti-XOIgG
XO 2 1088.70 5.00 17803 1.94032 -0.94079 0.91312 NO 1369 HXO
XO 2 1128.70 5.00 17791 1.27783 -0.58901 0.72335 NO 1357 r2
XO 2 1619.80 5.00 17763 1.16365 -0.58008 0.46952 NO 1329 H3
XO 2 1659.80 5.00 17758 0.98452 -0.23242 0.98755 NO 1324 r2
XO 2 2150.50 5.00 17758 1.39351 -0.29224 1.43306 NO 1324 B5
XO 2 2190.50 5.00 17752 0.30583 0.08309 0.29446 NO 1318 r2
XO 2 2507.40 5.00 16438 0.69305 -0.04833 0.76823 NO 4 reg
F ig u re  25. BIAcore surface plasm on resonance trace showing relative affinity of 
H 2C2 (anti-XOIgG in key) for ‘H X O ’ (i.e. possibly the 80 kD a contam inant of 
early H X O  preparations), and the subsequent lack of recognition by H 3G7 (H3 in 
key) and B5B4 (B5 in key). R U  = response, w hich is a relative value corresponding 
to association and dissociation between the test proteins.
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Anti-xoIgG/bovine XO
1 6 9 0 0  -
1 6 4 0 0  -
R
U
1 5 9 0 0  -
1 5 4 0 0  -
1 4 9 0 0
0 2 0 0 400 600 800 1 0 0 0 1 2 0 0 1400
Time [ s ]
APR0G FC Time Window AbsResp SO Slope LRSP Baseline RelResp Id
XO 2 57.60 5.00 16098 1.01242 0.16220 1.02883 YES 0 baselineXO 2 567.50 5.00 17034 0.90501 -0.35028 0.73153 NO 936 anti-xoIgGXO 2 1088.80 5.00 16959 1.81778 -0.66183 1.52745 NO 860 boviXOXO -s-^^ iU a .so 5.00 16949 1.08552 0.12074 1.12461 NO 851 r2XO 2 ittstee . 5.00 15975 0.87820 -0.34368 0.70429 NO -123 reg
F igure  26. BIAcore surface plasm on resonance trace showing lack of affinity of 
H2C2 (anti-XOIgG in key) for BXO (boviXO in key). R U  -  response, which is a 




1 6 9 0 0  -
1 6 7 0 0  -
1 6 5 0 0  -
1 6 3 0 0  -
R 1 6 1 0 0  - 
U
1 5 9 0 0  - 
1 5 7 0 0  - 
1 5 5 0 0  - 
1 5 3 0 0  -
1 5 1 0 0  ---------- 1---------- \---------- 1---------- 1----------1----------1---------- 1---------- 1----------1----------1—
0 5 0 0  1 0 0 0  1 5 0 0  2 0 0 0  2 5 0 0
I
Time [ s ]
APROG FC Time Window AbsResp SO Slope LRSO Baseline RelResp jd
XO 2 57.60 5.00 16220 0.45379 0.00399 0.50729 YES 0 baseline
XO 2 567.50 5.00 16305 0.58865 *0.28666 0.27132 NO 85 H3
XO 2 1088.60 5.00 16658 1.83053 -0.85279 1.00342 NO 439 blocking
XO 2 1128.60 5.00 16651 0.44684 -0.08583 0.46622 NO 432 r2
XO 2 1619.60 5.00 16704 2.43425 -1.02204 1.68433 NO 484 HXO
XO 2 1659.60 5.00 16692 0.33968 -0.01959 0.37756 NO 472 r2
XO 2 2150.40 5.00 16877 1.64261 -0.61853 1.30344 NO 657 anti-xoIgG
XO 2 2190.40 5.00 16867 1.04186 -0.29794 0.98412 NO 647 r2
XO 2 2507.00 5.00 16060 1.43575 0.02313 1.60449 NO -160 reg
F igure  27. BIAcore surface plasm on resonance trace showing relative affinity of 
H 3G 7 (H3 in key) for H X O , and subsequent association of H2C2 (anti-XOIgG in 
key). RU  = response, w hich is a relative value corresponding to  association and 
dissociation between the test proteins.
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B5/block/hX0/Anti-xoIgG
1 7 0 0 0
1 6 8 0 0  -
1 6 6 0 0  -
1 6 4 0 0  -
1 6 2 0 0  -
R 1 6 0 0 0  —*J 
U
1 5 8 0 0  -
1 5 6 0 0  -
1 5 4 0 0  -
1 5 2 0 0  -
1 5 0 0 0
1500 2 0 0 0 2 5 0 01 0 0 0500
Time [ s ]
APR0G £C Time Window AbsResp SD Slope LRSD Baseline RelResp Id
XO 2 57.40 5.00 15988 0.85962 •0.31401 0.70164 YES 0 baseline
XO 2 567.30 5.00 16079 1.02495 0.12084 1.11771 NO 91 B5
XO 2 1088.20 5.00 16471 1.96847 -0.90234 1.13198 NO 483 Blocking
XO 2 1128.20 5.00 16463 0.77676 -0.19235 0.76962 NO 476 r2
XO 2 1628.90 5.00 16500 1.08143 -0.24029 1.09966 NO 512 HXO
XO 2 2149.90 5.00 16668 1.54146 -0.62483 1.12342 NO 680 anti-XOlgG
XO 2 2189.90 5.00 16658 0.58971 0.22349 0.46495 NO 670 r2
XO 2 2506.70 5.00 15944 0.59568 0.14919 0.58836 NO -44 reg
F igure  28. BIAcore surface plasm on resonance trace showing relative affinity of 
B5B4 (B5 in key) for H X O , and subsequent association of H2C2 (anti-XOIgG in 
key). R U  = response, w hich is a relative value corresponding to association and 
dissociation between the test proteins.
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Appendix IV
In order to demonstrate that HXO  was immunogenic, and problems generating 
anti-(XOR) mAbs were not caused by restricted epitopes, the H X O  sequence was 
analysed using the program PeptideStructure. This is part of the Genetics 
Computer Group suite of programs (Devereux et al., 1984). Figure 29 shows the 
antigenicity profile of the protein (i.e. points in secondary structure where 
antigenic index >  1.2). Antigenic index (Al) is calculated by summing several 
weighted measures of the protein’s secondary structure; it is a measure of the 
probability that a region is antigenic.
This method of Al determination was first described by Jameson and 
Wolf (1988), and uses a formula which incorporates measurement of 
hydrophilicity, surface probability, flexibility, and Chou-Fasman and Robson- 
Garnier predictions of secondary structure.
From Figure 29, it appears that particularly antigenic regions lie between 
residues 150 and 200, and 800 and 1150.
Figure 30 shows plots for hydrophilicity, surface probability, flexibility, 
Al, Chou-Fasman and Robson-Garnier predictions of secondary structure, and 
predicted glycosylation sites on HXO.
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PLOTSTRUCTURE o f :  h s u 0 6 1 1 7 .s e q  ck: 9356 chou-F.s«an prediction
REFORMAT of: hsu06117.seq check: -1 from: 1 to: 1333 July 5. li?4 16:12July 5l 1594 16:22
Q  Antigen.Index >= 1.2
NH2
COOi
F igure  29. Antigenicity profile of HXO, determined using part of the Genetics 
Computer Group suite of programs (Devereux et al., 1984).
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PLOTSTRUCTURE of: hsu06117.p2s July 5, 1994 16:22
PEPTIDESTRUCTURE o f :  h s u 0 6 1 1 7 . s e q  Ck: 9356 ,  1 t o :  1333  
REFORMAT o f :  h s u 0 6 1 1 7 . s e q  c h e c k :  -1 from: 1 t o :  1333 J u l y  5 ,  1994 16 :12
S00 1.000
I I • I I I I I I I I I I I I I I I I I I I I I I I
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F ig u re  30. Summary of secondary structure characteristics of H X O , determ ined 
using part of the Genetics C om puter G roup  suite of programs 
(Devereux et al., 1984).
188
References
Abadeh S, Killacky J, Benboubetra M, Harrison R. Purification and partial 
characterization of xanthine oxidase from human milk. Biochim Biophys Acta 1992; 
1117:25-32.
Abadeh S, Case P, Harrison R. Purification of xanthine oxidase from human heart. 
Biochem Soc Trans 1993; 2 1 : 99S.
Adachi T, Fukushima T, Usami Y, Hirano K. Binding of human xanthine oxidase 
to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem J. 1993; 
289: 523-7.
Akizuki S, Yoshida S, Chamber DE et al. Infarct size limitation by the xanthine 
oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts. Cardiovasc 
Res 1985; 19: 686-92.
Amaya Y, Yamazaki K, Sato M, Noda K, Nishino T, Nishino T. Proteolytic 
conversion of xanthine dehydrogenase from the NAD-dependent type to the 0 2 - 
dependent type. J Biol Chem 1990; 265: 14170-5.
Avis PG, Bergel F, Bray RC. Cellular constituents. The chemistry of xanthine 
oxidase. Part III. Estimations of the cofactors and the catalytic activities of enzyme 
fractions from cow's milk. J Chem Soc 1956: 1219-25.
Avrameas S, Dighiero G, Lymberi P, Guilbert B. Studies on natural antibodies and 
autoantibodies. Ann Immunol 1983; 134D: 103-13.
BatteUi MG, Della Corte E, Stirpe F. Xanthine oxidase type D (dehydrogenase) in 
the intestine and other organs of the rat. Biochem ]  1972; 126: 747-9.
Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA. A sensitive 
flourometric assay for measuring xanthine dehydrogenase and oxidase in tissues. 
Free Rad Biol Med 1989; 6 : 607-15.
Berglund L, Rasmussen JT, Andersen MD, Rasmussen MS, Petersen TE. 
Purification of the bovine xanthine oxidoreductase from milk fat globule 
membranes and cloning of complementary deoxyribonucleic acid. J Dairy Sci 1996; 
79: 198-204.
Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
1976; 72: 248.
189
Bray RC. The chemistry of xanthine oxidase. Variations in stability and the 
presence of an inhibitor in certain preparations. Biochem J  1959; 73: 690-4.
Bray RC. Molybdenum iron-sulphur flavin hydroxylases and related enzymes. In: 
Boyer PD, ed. The Enzymes. New York: Academic Press, 1975: 299-419.
Briley MS, Eisenthal R. Association of xanthine oxidase with the bovine milk-fat- 
globule membrane. Biochem J 1974; 143: 149-57.
Brown AM, Benboubetra M, Ellison M et al. Molecular activation-deactivation of 
xanthine oxidase in human milk. Biochim Biophys Acta 1995; 1245: 248-54.
Bruder G, Heid HW, Jarasch E-D, Mather IH. Immunological identification and 
determination of xanthine oxidase in cells and tissues. Differentiation 1983; 23: 
218-25.
Bruder G, Heid HW, Jarasch E-D, Keenan TW, Mather IH. Characteristics of 
membrane-bound and soluble forms of xanthine oxidase from milk and endothelial 
cells of capillaries. Biochim Biophys Acta 1982; 701: 357-69.
Brunschede H , Krooth RS. Studies on the xanthine oxidase activity of mammalian 
cells. Biochem Gen 1973; 8 : 341-50.
Chambers DE, Parks DA, Patterson G et al. Xanthine oxidase as a source of free 
radical damage in myocardial ischemia. J  Mol Cell Cardiol 1985; 17: 145-52.
de Jong JW, van der Meer P, Nieukoop S, Huizer T, Stroeve RJ, Bos E. Xanthine 
oxidoreductase activity in perfused hearts of various species, including humans. 
CircRes 1990; 67: 770-3.
de Jong JW, van der Meer P, Huizer T, Serruys PW, Bos E, Roelandt JR. Does 
xanthine oxidase cause damage during myocardial ischemia? Bratisl Lek Listy 1991; 
92: 41-7.
Della Corte E, Stirpe F. Regulation of xanthine oxidase in rat liver: modifications 
of the enzyme activity of rat liver supernatant on storage at 20 degrees. Biochem J 
1968; 108: 349.
Della Corte E, Gozzetti G, Novello F, Stirpe F. Properties of the xanthine oxidase 
from human liver. Biochim Biophys Acta 1969; 191: 164-6.
190
Della Corte E, Stirpe F. The regulation of rat liver xanthine oxidase. Involvement 
of thiol groups in the conversion of the enzyme activity from dehydrogenase (type 
D) into oxidase (type O) and purification of the enzyme. Biochem J 1972; 126: 
739-45.
Devereux J, Haeberli P, Smithies G. A comprehensive set of sequence analysis 
programs for the Vax. Nucleic Acids Res 1984; 12: 387-95.
Downey JM, Miura T, Eddy LJ et al. Xanthine oxidase is not a source of free 
radicals in the ischemic rabbit heart. J Mol Cell Cardiol 1987; 19: 1053-60.
Dupont GP, Huecksteadt TP, Marshall BC, Ryan US, Michael JR, Hoidal JR. 
Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene 
expression in cultured rat pulmonary endothelial cells. J Clin Invest 1992; 89: 197— 
202.
Eddy LJ, Stewart JR, Jones HP, Engerson TD, McCord JM, Downey JM. Free 
radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am  J  
Physiol 1987; 253: 709-11.
Edmondson D, Ballou D, Van Heuvelen A, Palmer G, Massey V. Kinetic studies 
on the substrate reduction of xanthine oxidase. /  Biol Chem 1973; 248: 6135-44.
Eger BT, Nishino T, Nishino T, Eikmanns U, Pai EF. Crystallization and 
preliminary X-ray diffraction of xanthine oxidase isolated from bovine milk. In: 
Yagi K, ed. Flavins and flavoproteins. New York: Walter de Gruyter, 1994: 727-29.
Friedl HP, Till GO, Ryan US, Ward PA. Mediator-induced activation of xanthine 
oxidase in endothelial cells. FASEB J 1989; 3: 2512-18.
Furth-Walker D, Amy NK. Regulation of xanthine oxidase activity and 
immunologically detectable protein in rats in response to dietary protein and iron. 
JN utr  1987; 117: 1697-703.
Granger DN. Role of xanthine oxidase and granulocytes in ischaemia-reperfusion 
injury. A m  J  Physiol 1988; 255: 1269-75.
Green NM. A spectrophotometric assay for avidin and biotin based on binding of 
dyes by avidin. Biochem J 1965; 94: 23-4.
Grootveld M, Halliwell B, Moorhouse CP. Action of uric acid, allopurinol, and 
oxypurinol on the myeloperoxidase-derived oxidant hypochlorous acid. Free 
Radical Res Commun 1988; 4: 69-76.
191
Grum CM, Ragsdale RA, Ketai LH, Shlafer M. Absence of xanthine oxidase or 
xanthine dehydrogenase in the rabbit myocardium. Biochem Biophys Res Com 1986; 
141: 1104-8.
Grum CM, Gallagher KP, Kirsh MM, Shlafer M. Absence of detectable xandiine 
oxidase in human myocardium. /  Mol Cell Cardiol 1989; 2 1 : 263-7.
H art LI, McGartoll MA, Chapman HR, Bray RC. The composition of milk 
xanthine oxidase. Biochem J 1970; 116: 851-64.
Hellsten-Westing Y. Immunohistochemical localization of xanthine oxidase in 
human cardiac and skeletal muscle. Histochemistry 1993; 100: 215-22.
Hoey BM, Butler J, Halliwell B. O n the specificity of allopurinol and oxypurinol 
as inhibitors of xanthine oxidase: A pulse radiolysis determination of rate 
constants for reaction of allopurinol and oxypurinol with hydroxyl radicals. Free 
Radical Res Commun 1988; 4: 259-63.
H unt J, Massey V. Purification and properties of milk xanthine dehydrogenase./ 
Biol Chem 1992; 267: 21479-85.
Ichida K, Amaya Y, Noda K et a l Cloning of the cDNA encoding human xanthine 
dehydrogenase (oxidase): structural analysis of the protein and chromosomal 
location of the gene. Gene 1993; 133: 279-84.
Ichikawa M, Nishino T, Nishino T, Ichikawa A. Subcellular localization of 
xanthine oxidase in rat hepatocytes: high resolution immunoelectron microscope 
study combined with biochemical analysis. JHistochem Cytochem 1992; 40: 1097- 
103.
Ikegami T, Nishino T. The presence of desulfo xanthine dehydrogenase in purified 
and crude enzyme preparations from rat liver. Arch Biochem Biophys 1986; 247: 
254-60.
Itoh R, Nishino T, Usami C, Tsushima K. An immunological study of the changes 
in chicken liver xanthine dehydrogenase activity during dietary adaptation. J 
Biochem 1978; 84: 19-26.
Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting 
antigenic determinants. Comput Appl Biosci 1988; 4: 181-6.
Jarasch E-D, Bruder G, Heid HW. Significance of xanthine oxidase in capillary 
endothelial cells. Acta Physiol Scand 1986; 548: 39-46.
192
Jarasch E-D, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW. 
Localization of xanthine oxidase in mammary-gland epithelium and capillary 
endothelium. Cell 1981; 25: 67-82.
Johnstone A, Thorpe R. Immunochemistry in practice. Oxford: Blackwell 
Scientific Publications, 1990.
Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial 
of allopurinol in coronary bypass surgery. A m  Heart J  1991; 121: 20-4.
Kaminski ZW, Pohorecki R, Ballast CL, Domino EF. Three forms of xanthine: 
acceptor oxidoreductase in rat heart. CircRes 1986; 59: 628-32.
Kemeny DM. A practical guide to ELISA. Oxford: Pergamon Press, 1991.
Kinuta Y, Kimura M, Itokawa Y, Ishikawa M, Kikuchi H. Changes in xanthine 
oxidase in ischemic rat brain. ]  Neurosurg 1989; 71: 417-20.
Komai H, Massey V, Palmer G. The preparation and properties of deflavo 
xanthine oxidase.] Biol Chem 1969; 244: 1692-1700.
Kooij A, Bosch KS, Frederiks WM, Van Noorden CJF. High levels of xanthine 
oxidoreductase in endothelial, epithelial and connective tissue cells in rat tissues. A 
relation between localization and function? Virchows Arch B Cell Pathol 1992a; 62: 
143-50.
Kooij A, Schijns M, Frederiks WM, Van Noorden CJF, James J. Distribution of 
xanthine oxidoreductase activity in human tissues -  a histochemical and 
biochemical study. Virchows Arch B Cell Pathol 1992b; 63: 17-23.
Kooij A. A re-evaluation of the tissue distribution and physiology of xanthine 
oxidoreductase. Histochem J  1994; 26: 889-915.
Korthuis RJ, Granger DN. Reactive oxygen metabolites, neutrophils, and the 
pathogenesis of ischemic-tissue/reperfusion. Clin Cardiol 1993; 16: 19-26.
Krenitsky TA, Tuttle JV, Cattau EL, Wang P. A comparison of the distribution 
and electron specificities of xanthine oxidase and aldehyde oxidase. Comp Biochem 
Physiol 1974; 49: 687-703.
Krenitsky TA. Aldehyde oxidase and xanthine oxidase -  functional and 
evolutionary relationships. Biochem Pharmacol 1978; 27: 2763-4.
193
Krenitsky TA, Spector T, Hall WW. Xanthine oxidase from human liver: 
purification and characterization. Arch Biochem Biophys 1986; 247: 108-19.
Kukreja RC, Hess ML. The oxygen free radical system: from equations through 
membrane-protein interactions to cardiovascular injury and protection. Cardiovasc 
Res 1992; 26: 641-55.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 1970; 227: 680-5.
Lee PC. Effect of allopurinol treatment on tissue xanthine oxidase levels in mice. 
Arch Biochem Biophys 1973; 157: 322-3.
Lee N, Zhang S-Q, Testa D. A rapid multicolor Western blot. ]  Immunol Methods 
1988; 106: 27-30.
Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin 
phenol reagent .J  Biol Chem 1951; 193: 265.
Manning A, Bernier M, Crome R, Little S, Hearse D. Reperfusion-induced 
arrhythmias: a study of the role of xanthine oxidase-derived free radicals in the rat 
heart .J  Mol Cell Cardiol 1988; 20: 35-45.
Massey V, Brumby PE, Komai H, Palmer G. Studies on milk xanthine oxidase. /  
Biol Chem 1969; 244: 1682-91.
Massey V, Edmondson D. O n the mechanism of inactivation of xanthine oxidase 
by cyanide. /  Biol Chem 1970; 245: 6595-8.
McCord JM. Oxygen-derived free radicals: a link between reperfusion injury and 
inflammation. FedProc 1987; 46: 2402-6.
McCord JM. Oxygen-derived free radicals in postischaemic tissue injury. N  Enol J 
Med 1985; 312: 159-63.
McGartoll MA, Pick FM, Swann JC, Bray RC. Properties of xanthine oxidase 
preparations dependent on the proportions of activated and inactivated enzyme. 
Biochim Biophys Acta 1970; 212: 523-6.
Michiels C, Amould T, Houbion A, Remade J. Human umbilical endothelial cells 
submitted to hypoxia-reoxygenation in vitro: Implication of free radicals, xanthine 
oxidase, and energy deficiency. J  Cell Physiol 1992; 153: 53-61.
194
Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge JMC. 
Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 1987; 213: 
23-8.
Moriwaki Y, Yamamoto T, Suda M et al. Purification and immunohistochemical 
tissue localization of human xanthine oxidase. Biochim Biophys Acta 1993; 1164: 
327-30.
Mousson B, Desjacques, Baltassat P. Measurement of xanthine oxidase activity in 
some human tissues. An optimized method. Enzyme 1983; 29: 32-43.
Muxfeldt M, Schaper W. The activity of xanthine oxidase in heart of pigs, guinea 
pigs, rabbits, rats, and humans. Basic Res Cardiol 1987; 82: 486-92.
Nagler LG, Vartanyan LS. Subunit structure of bovine milk xanthine oxidase: 
Effect of limited cleavage by proteolytic enzymes on activity and structure. 
Biochim Biophys Acta 1976; 427: 78-90.
Nakamura M, Yamazaki I. Preparation of bovine milk xanthine oxidase as a 
dehydrogenase form . ]  Biochem 1982; 92: 1279-86.
Nishino T, Nishino T. The nicotinamide adenine dinucleotide-binding site of 
chicken Ever xanthine dehydrogenase. ]  Biol Chem 1989; 264: 5468-73.
Nishino T, Nishino T, Schopfer LM, Massey V. Reactivity of chicken liver 
xanthine dehydrogenase containing modified flavins. J Biol Chem 1989; 264: 6075- 
85.
NishinoT, Tamura I. The mechanism and conversion of xanthine dehydrogenase 
to oxidase and the role of the enzyme in reperfusion injury. In: Harkness RA et al., 
eds. Purine and pyrimidine metabolism in man VII, Part A. New York: Plenum 
Press, 1991: 327-333.
Nishino T, Tsushima K, Hille R, Massey V. Inhibition of milk xanthine oxidase 
by fluorodinitrobenzene. J Biol Chem 1982; 257: 7348-53.
Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and 
physiology. Acta Physiol Scand Suppl 1986; 548: 87-99.
Perez HD, Weksler BB, Goldstein I A. Generation of a chemotactic lipid from 
arachidonic acid by exposure to a superoxide-generating system. Inflammation 
1980; 4: 313-28.
195
Pfeffer KD, Huecksteadt TP, Hoidal JR. Xanthine dehydrogenase and xanthine 
oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid 
regulation. J Immunol 1994; 153: 1789-97.
Phan SH, Gannon DE, Varani J, Ryan US, Ward PA. Xanthine oxidase activity in 
rat pulmonary artery endothelial cells and its alteration by activated neutrophils. 
Am  J Pathol 1989; 134: 1201-11.
Phan SH, Gannon DE, Ward PA, Karmiol S. Mechanism of neutrophil-induced 
xanthine dehydrogenase to xanthine oxidase conversion in endothelial cells: 
evidence of a role for elastase. Am  J Respir Cell Mol Biol 1992; 6 : 270-8.
Podzuweit T, Beck H , Muller A, Bader R, Gorlach G, Scheld H H . Absence of 
xanthine oxidoreductase activity in human myocardium. Cardiovasc Res 1991; 25: 
820-30.
Powell D. Purification, characterization and regulation of xanthine oxidase. 
University of Bath: 1996.
Price LJ, Harrison R. Sensitive enzyme-linked immunosorbent assay (ELISA) for 
xanthine oxidase. Biochem Soc Trans 1993; 21: 102S.
Reimer KA, Jennings RB. Failure of the xanthine oxidase inhibitor allopurinol to 
limit infarct size after ischemia and reperfusion in dogs. Circulation 1985; 71: 1069- 
75.
Roy RS, McCord JM. Superoxide and ischemia: conversion of xanthine 
dehydrogenase to xanthine oxidase. In: Greenwald RA, Cohen G, eds. Oxy radicals 
and their scavenger systems. Volume 2. Cellular and medical aspects. New York: 
Elsevier, 1983: 145-53.
Saito T, Nishino T, Massey V. Differences in environment of FAD between NAD- 
dependent and 0 2-dependent types of rat Ever xanthine dehydrogenase shown by 
active site probe study. J  Biol Chem 1989; 264: 15930-5.
Saito T, Massey V, Nishino T. Light product of photoreactive 6 -azido-FAD bound 
to deflavo-milk xanthine oxidase. Biochemistry 1992; 31: 6305-11.
Samra ZQ, Oguro T, Fontaine R, Ashraf M. Immunocytochemical localization of 
xanthine oxidase in rat myocardium. ] Submicrosc CytolPathol 1991; 23: 379-90.
Schopfer LM, Massey V, Nishino T. Rapid reaction studies on the reduction and 
oxidation of chicken Ever xanthine dehydrogenase by the xanthine/urate and 
N A D /N A D H  couples. J Biol Chem 1988; 263: 13528-38.
196
Schoutsen B, de Jong JW, Harmsen E, de Tombe PP, Achterberg PW. Myocardial 
xanthine oxidase/dehydrogenase. Biochim Biophys Acta 1983; 762: 519-24.
Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently 
widely used messengers in the activation of the NF-kappa B transcription factor 
and HIV-1. EMBO J 1991; 10: 2247-58.
Shamma'a MH, Nasrallah S, Chaglassian T, Kachadurian AK, Al-Khaladi UAS. 
Serum xanthine oxidase: a sensitive test of acute liver injury. Gastroenterology 1965; 
48:26-230.
Smith JK, Carden DL, Grisham MB, Granger MB, Korthuis RJ. Role of iron in 
postischemic microvascular injury. A m ] Physiol 1989; 256: 1472-7.
Stell JGP, Wame AJ, Lee-Woolley C. Purification of rabbit liver aldehyde oxidase 
by affinity chromatography on benzamidine Sepharose 6 B. /  Chromatograph 1989; 
475:363-72.
Stirpe F, Della Corte E. The regulation of rat liver xanthine oxidase. Conversion in 
vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O).
J Biol Chem 1969; 244: 3855-63.
Terada LS, Rubinstein JD, Lesnefsky, EJ, Horwitz LD, Leff JA, Repine JE. 
Existence and participation of xanthine oxidase in reperfusion injury of ischemic 
rabbit myocardium. A m  J Physiol 1991; 260: 805-10.
Terada LS. Suppression of rabbit myocardial xanthine dehydrogenase activity by 
an endogenous compound. ] Mol Cell Cardiol 1994; 26: 125-32.
Varani J, Phan SH, Gibbs DF, Ryan US, Ward PA. H 2 0 2 -mediated cytotoxicity of 
rat pulmonary endothelial cells. Changes in adenosine triphosphate and purine 
products and effects of protective interventions. Lab Invest 1990; 63: 683-9.
Varani J, Ward PA. Mechanisms of endothelial cell injury in acute inflammation. 
Shock 1994; 2 : 311-19.
Ventom AM, Deistung J, Bray RC. The isolation of demolybdo xanthine oxidase 
from bovine milk. Biochem J  1988; 255: 949-56.
Wahl RC, Rajagopolan KV. Evidence for the inorganic nature of the cyanolyzable 
sulfur of molybdenum hydroxylases. J Biol Chem 1982; 257: 1354-9.
Wajner M, Harkness RA. Distribution of xanthine dehydrogenase and oxidase 
activities in human and rabbit tissues. Biochim Biophys Acta 1989; 991: 79-84.
197
Wame A, Stell JGP. Purification of aldehyde oxidase from liver by affinity 
chromatography and FPLC. J  Pharm BiomedAnal 1990; 8 : 1015-19.
Watts RWE, Watts JEM, Seegmiller JE. Xanthine oxidase activity in human tissues 
and its inhibition by allopurinol (4-hydroxypyrazolo [3,4-d] pyrimidine). J Lab 
Clin Med 1965; 6 6 : 688-97.
Waud WR, Rajapolan KV. The mechanism of conversion of rat liver xanthine 
dehydrogenase from an N A D +-independent form (type D) to an Ch-dependent 
form (type O). Arch Biochem Biophys 1976a; 172: 365-79.
Waud WR, Rajapolan KV. Purification and properties of the N A D +-dependent 
form (type D) and Ch-dependent form (type O) of rat liver xanthine 
dehydrogenase. Arch Biochem Biophys 1976b; 172: 354-64.
Wems SW, Shea MJ, Mitsos SE et al. Reduction of the size of infarction by 
allopurinol in the ischemic-reperfused canine heart. Circulation 1986; 73: 518-24.
Wems SW, Lucchesi BR. Free radicals and ischemic tissue injury. TIPS 1990; 11: 
161-6.
Wems SW, Grum CM, Ventura A et al. Xanthine oxidase inhibition does not limit 
canine infarct size. Circulation 1991; 83: 995-1005.
Winrow VR, Winyard PG, Morris CJ, Blake DR. Free radicals in inflammation: 
second messengers and mediators of tissue destmction. BrMed Bull 1993; 49:
506-22.
Woolfolk CA, Downard JS. Distribution of xanthine oxidase and xanthine 
dehydrogenase specificity types among bacteria. J Bacteriol 1977; 130: 1175-91.
Xu P, Huecksteadt TP, Harrison R, Hoidal JR. Molecular cloning, tissue 
expression of human xanthine dehydrogenase. Biochem Biophys Res Com 1994; 199: 
998-1004.
Yellon DM, Maxwell MP, Hearse DJ, Yoshida S, Eddy L, Downey JM.
Infarct-size limitation -  real or artifactual. Studies with flurbiprofen using a 
reperfusion model. Adv Myocardiol 1985; 6 : 619-27.
Zikakis JP, McGinnis G. Purification and some properties of human colostral 
xanthine oxidase. In: Charalambous G, ed. Frontiers o f flavour. Amsterdam:
Elsevier Science, 1988: 429-42.
198
